PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) (English)
- New search for: Fowler, N. H.
- New search for: Dickinson, M.
- New search for: Martinez‐Lopez, J.
- New search for: Kolstad, A.
- New search for: Schuster, S. J.
- New search for: Dreyling, M.
- New search for: Ghosh, M.
- New search for: Harigae, H.
- New search for: Kersten, M. José
- New search for: Bachy, E.
- New search for: Popplewell, L.
- New search for: Chavez, J. C.
- New search for: Ho, P. J.
- New search for: Butler, J.
- New search for: Kato, K.
- New search for: von Tresckow, B.
- New search for: Ferreri, A. J. M.
- New search for: Simón, J. A. P.
- New search for: Patten, P. E. M.
- New search for: Andreadis, C.
- New search for: Riedell, P. A.
- New search for: McGuirk, J. P.
- New search for: Nastoupil, L. J.
- New search for: Teshima, T.
- New search for: Offner, F.
- New search for: Petzer, A.
- New search for: Viardot, A.
- New search for: Zinzani, P. L.
- New search for: Malladi, R.
- New search for: Zhang, J.
- New search for: Tiwari, R.
- New search for: Bollu, V.
- New search for: Masood, A.
- New search for: Thieblemont, C.
- New search for: Fowler, N. H.
- New search for: Dickinson, M.
- New search for: Martinez‐Lopez, J.
- New search for: Kolstad, A.
- New search for: Schuster, S. J.
- New search for: Dreyling, M.
- New search for: Ghosh, M.
- New search for: Harigae, H.
- New search for: Kersten, M. José
- New search for: Bachy, E.
- New search for: Popplewell, L.
- New search for: Chavez, J. C.
- New search for: Ho, P. J.
- New search for: Butler, J.
- New search for: Kato, K.
- New search for: von Tresckow, B.
- New search for: Ferreri, A. J. M.
- New search for: Simón, J. A. P.
- New search for: Patten, P. E. M.
- New search for: Andreadis, C.
- New search for: Riedell, P. A.
- New search for: McGuirk, J. P.
- New search for: Nastoupil, L. J.
- New search for: Teshima, T.
- New search for: Offner, F.
- New search for: Petzer, A.
- New search for: Viardot, A.
- New search for: Zinzani, P. L.
- New search for: Malladi, R.
- New search for: Zhang, J.
- New search for: Tiwari, R.
- New search for: Bollu, V.
- New search for: Masood, A.
- New search for: Thieblemont, C.
In:
Hematological Oncology
;
39
;
2021
- Article (Journal) / Electronic Resource
-
Title:PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
-
Contributors:Fowler, N. H. ( author ) / Dickinson, M. ( author ) / Martinez‐Lopez, J. ( author ) / Kolstad, A. ( author ) / Schuster, S. J. ( author ) / Dreyling, M. ( author ) / Ghosh, M. ( author ) / Harigae, H. ( author ) / Kersten, M. José ( author ) / Bachy, E. ( author )
-
Published in:
-
Publisher:
-
Publication date:2021-06-01
-
Size:1 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 39
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Issue Information| 2021
- 3
-
The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitorsMenter, Thomas / Tzankov, Alexandar / Dirnhofer, Stefan et al. | 2021
- 7
-
16th International Conference on Malignant Lymphoma Virtual Edition 18 ‐ 22 June, 2021| 2021
- 7
-
ACKNOWLEDGEMENTS| 2021
- 11
-
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignanciesTanaka, Junji et al. | 2021
- 13
-
SCIENTIFIC PROGRAM (updated on June 2, 2021)| 2021
- 15
-
Langerhans cell histiocytosis: Version 2021Gulati, Nitya / Allen, Carl E. et al. | 2021
- 20
-
Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxisCairoli, Roberto / Ferrara, Felicetto / Girmenia, Corrado / Luppi, Mario / Pea, Federico / Specchia, Giorgina / Venditti, Adriano et al. | 2021
- 24
-
Molecular classification of aggressive lymphomas—past, present, futureWienand, Kirsty / Chapuy, Björn et al. | 2021
- 26
-
ORAL PRESENTATIONS| 2021
- 27
-
The role of long non‐coding RNAs and downstream signaling pathways in leukemia progressionLiu, Yadong / Sun, Penghao / Zhao, Yuhao / Liu, Bin et al. | 2021
- 31
-
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approachesSilkenstedt, Elisabeth / Dreyling, Martin et al. | 2021
- 39
-
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cureLongley, Jemma / Johnson, Peter W. M. et al. | 2021
- 41
-
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myelomaRocchi, Serena / Tacchetti, Paola / Pantani, Lucia / Mancuso, Katia / Rizzello, Ilaria / di Giovanni Bezzi, Chiara / Scalese, Marco / Dozza, Luca / Marzocchi, Giulia / Martello, Marina et al. | 2021
- 46
-
Cutaneous T‐cell lymphomas—An update 2021Kempf, Werner / Mitteldorf, Christina et al. | 2021
- 51
-
Consolidation with 90Yttrium‐ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphomaMiura, Katsuhiro / Tsujimura, Hideki / Masaki, Yasufumi / Iino, Masaki / Takizawa, Jun / Maeda, Yoshinobu / Yamamoto, Kazuhiko / Tamura, Shinobu / Yoshida, Akiyo / Yagi, Hideo et al. | 2021
- 52
-
What's new in peripheral T‐cell lymphomasLuminari, Stefano / Skrypets, Tetiana et al. | 2021
- 60
-
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomasVannata, Barbara / Vanazzi, Anna / Negri, Mara / Liptrott, Sarah Jayne / Bartosek, Anna Amalia / Miani, Monica / Di Sanzo, Alessandro / Cavalli, Franco / Zucca, Emanuele / Stathis, Anastasios et al. | 2021
- 61
-
Recognizing but not harming. Borderline B‐cell lymphoid proliferationsQuintanilla‐Martinez, Leticia et al. | 2021
- 66
-
Hematopoietic stem cell transplantation for diffuse large B‐cell lymphoma having 8q24/MYC rearrangement in JapanTakahashi, Tsutomu / Suzuki, Ritsuro / Yamamoto, Go / Nakazawa, Hideyuki / Kurosawa, Mitsutoshi / Kobayashi, Tsutomu / Okada, Masaya / Akasaka, Takashi / Kim, Sung‐Won / Fukuda, Takahiro et al. | 2021
- 68
-
Sequencing of myeloma therapy: Finding the right path among many standardsRajkumar, S. Vincent et al. | 2021
- 73
-
Molecular diagnostics and reporting in lymphoid malignancies: Current status and beyondRosenquist, Richard et al. | 2021
- 75
-
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infectionCui, Rui / Lyu, Cuicui / Li, Qing / Jiang, Yanyu / Mou, Nan / Yang, Zhenxing / Liu, Xuxiang / Deng, Qi / Li, Lanfang et al. | 2021
- 78
-
New drugs and pharmacological interactions in real lifeStathis, Anastasios et al. | 2021
- 83
-
Vulnerabilities in the tumor and microenvironment in follicular lymphomaAraujo‐Ayala, Ferran / Pérez‐Galán, Patricia / Campo, Elias et al. | 2021
- 87
-
Outcomes of second hematopoietic stem cell transplantation using reduced‐intensity conditioning in an outpatient settingJaime‐Pérez, José Carlos / Picón‐Galindo, Ernesto / Herrera‐Garza, José Luis / Gómez‐Almaguer, David et al. | 2021
- 88
-
Upfront identification of high‐risk follicular lymphomaCasulo, Carla et al. | 2021
- 94
-
High‐risk follicular lymphoma: Treatment optionsKahl, Brad et al. | 2021
- 97
-
Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantationBetticher, Christophe / Bacher, Ulrike / Legros, Myriam / Zimmerli, Stefan / Banz, Yara / Mansouri Taleghani, Behrouz / Pabst, Thomas et al. | 2021
- 100
-
Allogeneic stem cell transplant in non‐Hodgkin lymphomas: Still an indication?Dreger, Peter et al. | 2021
- 104
-
Optimizing CAR T cell therapy in lymphomaQualls, David / Salles, Gilles et al. | 2021
- 105
-
Clinical trial risk in leukemia: Biomarkers and trial designLi, Alice J. / Dhanraj, Jasper P. / Lopes, Gilberto / Parker, Jayson L. et al. | 2021
- 113
-
Bispecific antibodies for the treatment of lymphomas: Promises and challengesSchuster, Stephen J. et al. | 2021
- 114
-
Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy studyTudesq, Jean‐Jacques / Valade, Sandrine / Galicier, Lionel / Zafrani, Lara / Boutboul, David / de Bazelaire, Cédric / Munoz‐Bongrand, Nicolas / Canet, Emmanuel / Ardisson, Fanny / Lemiale, Virginie et al. | 2021
- 123
-
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter seriesIurlo, Alessandra / Palandri, Francesca / Maria Elli, Elena / Cattaneo, Daniele / Bucelli, Cristina / Sciumè, Mariarita / Vincelli, Donatella / Brioschi, Filippo / Auteri, Giuseppe / Croci, Giorgio Alberto et al. | 2021
- 129
-
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimenKreiniz, Natalia / Garty‐Ofir, Maya / Bejar, Jacob / Polliack, Aaron / Tadmor, Tamar et al. | 2021
- 134
-
Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem‐cell transplantation: Real‐life experienceBuccheri, Valeria / Fatobene, Giancarlo / Santos, Fernanda M. / Velasques, Rodrigo D. / Bellesso, Marcelo / Atanazio, Marcelo J. / Rocha, Vanderson et al. | 2021
- 137
-
Extended follow‐up of CD4+ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustineGaiolla, Rafael / Hartley, Sarah / Beech, Amy / Knight, Helen / Smith, Dean / Bishton, Mark / Fox, Christopher P. / Martinez‐Calle, Nicolas et al. | 2021
- 141
-
Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patientsCassin, Ramona / Visentin, Andrea / Giannarelli, Diana / Noto, Alessandro / Mauro, Francesca Romana / Baldini, Luca / Trentin, Livio / Reda, Gianluigi et al. | 2021
- 145
-
B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphomaTorisu, Takehiro / Kawano, Shinichi / Miyawaki, Kohta / Yamamoto, Hidetaka / Ihara, Yutaro / Matsuno, Yuichi / Torisu, Kumiko / Sugio, Takeshi / Sasaki, Kensuke / Shimakawa, Takashi et al. | 2021
- 145
-
E‐POSTERS| 2021
- 151
-
How to select older patients with acute myeloid leukemia fit for intensive treatment?Sustkova, Zuzana / Semerad, Lukas / Weinbergerova, Barbora / Mayer, Jiri et al. | 2021
- 162
-
Research progress on exosomes derived from mesenchymal stem cells in hematological malignanciesLyu, Tianxin / Zhang, Binglei / Li, Mengjia / Jiao, Xueli / Song, Yongping et al. | 2021
- 170
-
Trimethoprim‐sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literatureKing, Liam D. / Sia, Hanlon / Anoopkumar‐Dukie, Shailendra et al. | 2021
- 176
-
Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: A single‐institution experience on 1247 installations in 94 consecutive patientsAnton, Seena / Margold, Michelle / Kowalski, Thomas / Miller, Dorothea / Schmieder, Kirsten / Schlegel, Uwe / Seidel, Sabine et al. | 2021
- 185
-
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 studyHutchings, Martin / Radford, John / Ansell, Stephen M. / Illés, Árpád / Sureda, Anna / Connors, Joseph M. / Sýkorová, Alice / Shibayama, Hirohiko / Abramson, Jeremy S. / Chua, Neil S. et al. | 2021
- 196
-
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in SwitzerlandMoccia, A. A. / Aeppli, S. / Güsewell, S. / Bargetzi, M. / Caspar, C. / Brülisauer, D. / Ebnöther, M. / Fehr, M. / Fischer, N. / Ghilardi, G. et al. | 2021
- 205
-
Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B‐cell lymphomaDonati, Benedetta / Ferrari, Angela / Ruffini, Alessia / Manzotti, Gloria / Fragliasso, Valentina / Merli, Francesco / Zanelli, Magda / Valli, Riccardo / Luminari, Stefano / Ciarrocchi, Alessia et al. | 2021
- 215
-
Obinutuzumab‐related adverse events: A systematic review and meta‐analysisAmitai, Irina / Gafter‐Gvili, Anat / Shargian‐Alon, Liat / Raanani, Pia / Gurion, Ronit et al. | 2021
- 222
-
Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by rapamycin and MYCN depletionKong, Desheng / Fan, Shengjin / Sun, Lili / Chen, Xi / Zhao, Yanqiu / Zhao, Linlin / Guo, Zhibo / Li, Yinghua et al. | 2021
- 231
-
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study groupMpakou, Vassiliki / Spathis, Aris / Bouchla, Anthi / Tsakiraki, Zoi / Kontsioti, Frieda / Papageorgiou, Sotirios / Bazani, Efthymia / Gkontopoulos, Konstantinos / Thomopoulos, Thomas / Glezou, Irene et al. | 2021
- 243
-
Hsa_circ_0002483 regulates miR‐758‐3p/MYC axis to promote acute myeloid leukemia progressionXiao, Yi / Ming, Xi / Wu, Jiaying et al. | 2021
- 254
-
Acute myeloid leukemia arising from polycythemia vera underwent reversion to chronic phase of myeloproliferative neoplasm status post chemotherapy: Biclonal myeloid neoplasms with genomic evidence of a common early hematopoietic progenitorZhao, Yue / Sotolongo, Gina / Deak, Kristen / Wang, Endi et al. | 2021
- 258
-
Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and traditionBelia, Marina / Chatzidimitriou, Chrysovalantou / Rondogianni, Phivi / Petsa, Panayiota / Efstathopoulou, Maria / Konstantinou, Eliana / Arapaki, Maria / Asimakopoulos, John / Plata, Eleni / Konstantopoulos, Kostas et al. | 2021
- 263
-
Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomasMerli, Michele / Marino, Dario / Cencini, Emanuele / Rattotti, Sara / Fraenza, Costanza / Grossi, Paolo / Bianchi, Benedetta / Mora, Barbara / Sciarra, Roberta / Finotto, Silvia et al. | 2021
- 267
-
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantationInnocenti, Idanna / Sora, Federica / Autore, Francesco / Chiusolo, Patrizia / Giammarco, Sabrina / Metafuni, Elisabetta / Bacigalupo, Andrea / Sica, Simona / Laurenti, Luca et al. | 2021
- 270
-
Therapeutic targets in childhood B‐acute lymphoblastic leukemia: what about HER2/neu?Camuset, Margaux / Huault, Alice / Grain, Audrey / Clémenceau, Béatrice / Rialland, Fanny / Thomas, Caroline / Chevallier, Patrice / Béné, Marie C. / Eveillard, Marion et al. | 2021
- 275
-
Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous LymphomaZinzani, Pier Luigi / Quaglino, Pietro / Violetti, Silvia Alberti / Cantonetti, Maria / Goteri, Gaia / Onida, Francesco / Paulli, Marco / Rupoli, Serena / Barosi, Giovanni / Pimpinelli, Nicola et al. | 2021
- 284
-
High‐grade B‐cell lymphomas with MYC and BCL2 translocations lack tumor‐associated macrophages and PD‐L1 expression: A possible noninflamed subgroupBreinholt, Marie F. / Oliveira, Douglas V. N. P. / Klausen, Tobias W. / Gang, Anne O. / Schejbel, Lone / Pedersen, Mette Ø. / Elbæk, Mette V. / Clasen‐Linde, Erik / Nielsen, Signe L. / Knudsen, Helle et al. | 2021
- 293
-
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaGenuardi, Elisa / Klous, Petra / Mantoan, Barbara / Drandi, Daniela / Ferrante, Martina / Cavallo, Federica / Alessandria, Beatrice / Dogliotti, Irene / Grimaldi, Daniele / Ragaini, Simone et al. | 2021
- 304
-
Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapyChelius, Monica / Chau, Karen / Yang, Joanna / Hajj, Carla / Imber, Brandon / Yahalom, Joachim et al. | 2021
- 313
-
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic NeoplasmsKnauf, Wolfgang / Abenhardt, Wolfgang / Koenigsmann, Michael / Maintz, Christoph / Sandner, Reiner / Zahn, Mark‐Oliver / Schnell, Roland / Tech, Susanne / Kaiser‐Osterhues, Anja / Houet, Leonora et al. | 2021
- 326
-
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupRigolin, Gian Matteo / Cavazzini, Francesco / Piciocchi, Alfonso / Arena, Valentina / Visentin, Andrea / Reda, Gianluigi / Zamprogna, Giulia / Cibien, Francesca / Vitagliano, Orsola / Coscia, Marta et al. | 2021
- 336
-
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomasDimou, Maria / Papageorgiou, Sotirios G. / Stavroyianni, Niki / Katodritou, Eirini / Tsirogianni, Maria / Kalpadakis, Christina / Banti, Anastasia / Arapaki, Maria / Iliakis, Theodoros / Bouzani, Maria et al. | 2021
- 349
-
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myelomaTakakuwa, Teruhito / Ohta, Kensuke / Nakatani, Eiji / Ito, Tomoki / Kaneko, Hitomi / Fuchida, Shin‐Ichi / Shimura, Yuji / Yagi, Hideo / Shibayama, Hirohiko / Kanda, Junya et al. | 2021
- 358
-
Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemiaMeng, Tongyan / Qi, Jiaqian / Zhu, Yuanxin / Xu, Yang / Chen, Feng / Xue, Shengli / Miao, Miao / Chen, Suning / Han, Yue / Tang, Xiaowen et al. | 2021
- 364
-
FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemiaCassaro, Adriana / Grillo, Giovanni / Notaro, Marco / Gliozzo, Jessica / Esposito, Ilaria / Reda, Gianluigi / Trojani, Alessandra / Valentini, Giorgio / Di Camillo, Barbara / Cairoli, Roberto et al. | 2021
- 380
-
Mesenchymal stem cells enhance the impact of KIR receptor‐ligand mismatching on acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemiaZhang, Yu / Zheng, Hao / Ren, Jinhua / Luo, Xiaofeng / Zheng, Zhihong / Zheng, Jing / Zheng, Xiaoyun / Chen, Yi / Chen, Zhizhe / Hu, Jianda et al. | 2021
- 384
-
PUBLICATION| 2021
- 390
-
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axisWang, Di / Ming, Xi / Xu, Jinhuan / Xiao, Yi et al. | 2021
- 401
-
Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitorsLatagliata, Roberto / Attolico, Immacolata / Trawinska, Malgorzata Monika / Capodanno, Isabella / Annunziata, Mario / Elena, Chiara / Luciano, Luigiana / Crugnola, Monica / Bergamaschi, Micaela / Bonifacio, Massimiliano et al. | 2021
- 409
-
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsBenevolo, Giulia / Elli, Elena M. / Bartoletti, Daniela / Latagliata, Roberto / Tiribelli, Mario / Heidel, Florian H. / Cavazzini, Francesco / Bonifacio, Massimiliano / Crugnola, Monica / Binotto, Gianni et al. | 2021
- 419
-
Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvementde‐la‐Fuente, Cristina / Nuñez, Fidel / Cortés‐Romera, Montserrat / Franch‐Sarto, Mireia / Ribera, Josep‐Maria / Sancho, Juan‐Manuel et al. | 2021
- 423
-
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemiaFresa, Alberto / Autore, Francesco / Innocenti, Idanna / Piciocchi, Alfonso / Tomasso, Annamaria / Morelli, Francesca / Sorà, Federica / Sica, Simona / De Stefano, Valerio / Laurenti, Luca et al. | 2021
- 428
-
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infectionCandoni, Anna / Pizzano, Umberto / Fabris, Martina / Curcio, Francesco / Fanin, Renato et al. | 2021
- 431
-
Intrahospital COVID‐19 infection outbreak management: Keep calm and carry onFrustaci, Anna M. / Pioltelli, Maria L. / Ravano, Emanuele / Di Ruscio, Federica / Campisi, Daniela A. / Puoti, Massimo / Cairoli, Roberto et al. | 2021
- 434
-
Erratum| 2021
- 439
-
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapyMazzaro, Cesare / Dal Maso, Luigino / Visentini, Marcella / Ermacora, Anna / Andreone, Pietro / Gattei, Valter / Pozzato, Gabriele et al. | 2021
- 448
-
Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysisBastin, Donald J. / Khan, Sarwat T. / Montroy, Joshua / Kennedy, Michael A. / Forbes, Nicole / Martel, Andre B / Baker, Laura / Gresham, Louise / Boucher, Dominique M. / Wong, Boaz et al. | 2021
- 465
-
Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomasTakezaki, Toshiaki / Nakazaki, Kumi / Toyama, Kazuhiro / Matsuda, Kensuke / Kogure, Yasunori / Chiba, Akira / Nakamura, Fumihiko / Honda, Akira / Kurokawa, Mineo et al. | 2021
- 473
-
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysisD’Angelo, Christopher R. / Hanel, Walter / Chen, Yi / Yu, Menggang / Yang, David / Guo, Ling / Karmali, Reem / Burkart, Madelyn / Ciccosanti, Colleen / David, Kevin et al. | 2021
- 483
-
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphomaWada, Fumiya / Shimomura, Yoshimitsu / Yabushita, Tomohiro / Yamashita, Daisuke / Ohno, Aya / Imoto, Hiroharu / Maruoka, Hayato / Hara, Shigeo / Ishikawa, Takayuki et al. | 2021
- 485
-
INDUSTRY PROGRAM ‐ SATELLITE SYMPOSIUM AGENDA| 2021
- 490
-
Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab eraGuan, Qingpei / Hong, Yuheng / Hu, Ge / Zhou, Qiqi / Li, Lanfang / Qian, Zhengzi / Zhou, Shiyong / Ren, Xiubao / Qiu, Lihua / Wang, Xianhuo et al. | 2021
- 494
-
INDUSTRY PROGRAM ‐ SATELLITE SYMPOSIUM ABSTRACT| 2021
- 495
-
Author Index| 2021
- 498
-
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective studyAkay, Olga Meltem / Ozbalak, Murat / Pehlivan, Mustafa / Yildiz, Birol / Uzay, Ant / Yigenoglu, Tugce Nur / Elverdi, Tugrul / Kaynar, Leylagul / Ayyildiz, Orhan / Yonal Hindilerden, Ipek et al. | 2021
- 506
-
Long‐term follow‐up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology GroupNúñez‐García, Beatriz / Rodríguez‐Pertierra, Marta / Sequero, Silvia / Carvajal, Laura G. / Ruano‐Ravina, Alberto / Aguiar, David / Gumá, Josep / Blanco, Cristina Q. / García Arroyo, Francisco R. / Garitaonaindia, Yago et al. | 2021
- 513
-
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemiaKriston, Csilla / Hernádfői, Márk / Plander, Márk / Márk, Ágnes / Takács, Ferenc / Czeti, Ágnes / Szalóki, Gábor / Szabó, Orsolya / Matolcsy, András / Barna, Gábor et al. | 2021
- 521
-
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patientsHøjholt, Karen Louise / Gregersen, Henrik / Szabo, Agoston Gyula / Klausen, Tobias Wirenfeldt / Levring, Mette Bøegh / Preiss, Birgitte / Helleberg, Carsten / Breinholt, Marie Fredslund / Hermansen, Emil / Rahbek Gjerdrum, Lise Mette et al. | 2021
- 529
-
Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trialsRibera, Josep‐Maria / Morgades, Mireia / Genescà, Eulàlia / Chapchap, Eduardo‐Cerello / Montesinos, Pau / Acuña‐Cruz, Evelyn / Gil, Cristina / García‐Cadenas, Irene / Barba, Pere / González‐Campos, José et al. | 2021
- 539
-
Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR‐625‐5p/SOX12 axisShang, Zhen / Ming, Xi / Wu, Jiaying / Xiao, Yi et al. | 2021
- 549
-
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experienceUreshino, Hiroshi / Kamachi, Kazuharu / Nishioka, Atsujiro / Okamoto, Sho / Katsuya, Hiroo / Yoshimura, Mariko / Kubota, Yasushi / Ando, Toshihiko / Kimura, Shinya et al. | 2021
- 558
-
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access studyPassamonti, Francesco / Gupta, Vikas / Martino, Bruno / Foltz, Lynda / Zaritskey, Andrey / Al‐Ali, Haifa Kathrin / Tavares, Renato / Maffioli, Margherita / Raanani, Pia / Giraldo, Pilar et al. | 2021
- 567
-
RBCK1‐TRIB3 decelerated the progression of acute promyelocytic leukemiaZhang, Xiang / Yu, Wenjuan et al. | 2021
- 570
-
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL reportCuneo, Antonio / Rigolin, Gian Matteo / Coscia, Marta / Quaresmini, Giulia / Scarfò, Lydia / Mauro, Francesca Romana / Motta, Marina / Quaglia, Francesca Maria / Trentin, Livio / Ferrario, Andrea et al. | 2021
- 575
-
Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patientsLucijanic, Marko / Huzjan Korunic, Renata / Ivic, Marija / Fazlic Dzankic, Amina / Kusec, Rajko / Pejsa, Vlatko et al. | 2021
- 580
-
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplantPapayannidis, Cristina / Sartor, Chiara / Dominietto, Alida / Zappone, Elisabetta / Arpinati, Mario / Marconi, Giovanni / Cristiano, Gianluca / Nanni, Jacopo / Parisi, Sarah / Barbato, Francesco et al. | 2021
- 584
-
Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancyPatel, Vishesh / Cameron, Donald William / Cowan, Juthaporn et al. | 2021
- 589
-
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosisTrotti, Chiara / Sant’Antonio, Emanuela / Vanni, Daniele / Casetti, Ilaria Carola / Borsani, Oscar / Pietra, Daniela / Ferretti, Virginia Valeria / Astori, Cesare / Arcaini, Luca / Rumi, Elisa et al. | 2021
- 595
-
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agentsMolica, Stefano / Seymour, John F. / Polliack, Aaron et al. | 2021
- 605
-
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphomaWang, Haoran / Zhang, Wentao / Yang, Jingyi / Zhou, Keshu et al. | 2021
- 616
-
Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphomaYu, Hao / Fu, Di / Xu, Peng‐Peng / Cheng, Shu / Wang, Li / Zhang, Yun‐Zeng / Zhao, Wei‐Li et al. | 2021
- 625
-
Combined tumor‐associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphomaSun, Xiaoqing / Wang, Caiqin / Chen, Cui / Huang, Jiajia / Wu, Xianqiu / Wang, Yu / He, Xiaohua / Cao, Jianghua / Jiang, Wenqi / Sun, Peng et al. | 2021
- 639
-
Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluationMozas, Pablo / Rivero, Andrea / Rivas‐Delgado, Alfredo / Correa, Juan Gonzalo / Condom, Maria / Nadeu, Ferran / Giné, Eva / Delgado, Julio / Villamor, Neus / Campo, Elías et al. | 2021
- 650
-
Outcomes of hematopoietic cell transplantation for transformed follicular lymphomaIda, Hanae / Inamoto, Yoshihiro / Fukuhara, Suguru / Maeshima, Akiko Miyagi / Takeda, Wataru / Hirakawa, Tsuneaki / Kuno, Masatomo / Aoki, Jun / Tanaka, Takashi / Ito, Ayumu et al. | 2021
- 658
-
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg typeKraft, Robert M. / Ansell, Stephen M. / Villasboas, Jose C. / Bennani, N. Nora / Wang, Yucai / Habermann, Thomas M. / Thanarajasingam, Gita / Lester, Scott C. / Macon, William / Inwards, David J. et al. | 2021
- 664
-
Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysisKim, Jinchul / Cho, Jinhyun / Byeon, Seonggyu / Kim, Won Seog / Kim, Seok Jin et al. | 2021
- 674
-
Secondary primary malignancies in patients with multiple myeloma: A single institution experienceFei, Fei / Reddy, Vishnu / Rosenblum, Frida et al. | 2021
- 680
-
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemiaAnsuinelli, Michela / Della Starza, Irene / Lauretti, Alessia / Elia, Loredana / Siravo, Veronica / Messina, Monica / De Novi, Lucia Anna / Taherinasab, Akram / Canichella, Martina / Guarini, Anna et al. | 2021
- 687
-
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemiaMesegué, Montserrat / Alonso‐Saladrigues, Anna / Pérez‐Jaume, Sara / Comes‐Escoda, Ariadna / Dapena, José Luís / Faura, Anna / Conde, Nuria / Català, Albert / Ruiz‐Llobet, Anna / Zapico‐Muñiz, Edgar et al. | 2021
- 697
-
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemiaDoucette, Kimberley / Percival, Mary‐Elizabeth / Williams, Lacey / Kandahari, Adrese / Taylor, Allison / Wang, Shuqi / Ahn, Jaeil / Karp, Judith E. / Lai, Catherine et al. | 2021
- 707
-
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYCBenatti, Stefania / Atene, Claudio Giacinto / Fiorcari, Stefania / Mesini, Nicolò / Martinelli, Silvia / Zucchini, Patrizia / Bacchelli, Francesca / Maccaferri, Monica / Debbia, Giulia / Potenza, Leonardo et al. | 2021
- 712
-
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patientsDel Poeta, Giovanni / Bomben, Riccardo / Polesel, Jerry / Rossi, Francesca Maria / Pozzo, Federico / Zaina, Eva / Cattarossi, Ilaria / Varaschin, Paola / Nanni, Paola / Boschian Boschin, Romina et al. | 2021
- 715
-
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patientsWeinbergerova, Barbora / Mayer, Jiri / Kabut, Tomas / Hrabovsky, Stepan / Prochazkova, Jirina / Kral, Zdenek / Herout, Vladimir / Pacasova, Rita / Zdrazilova‐Dubska, Lenka / Husa, Petr et al. | 2021
- 721
-
On the relevance of immunodeficiency evaluation in haematological cancerSánchez‐Ramón, Silvia / Chapel, Helen / Cunningham‐Rundles, Charlotte et al. | 2021
- 724
-
Racial disparities in hospitalization outcomes among adult multiple myeloma patients using the national inpatient sample (2016–2018)Jackson, Inimfon / Musoke, Nancy et al. | 2021
- 728
-
Is race important in genomic classification of hematological neoplasms?Huang, Huijun / Wu, Junying / Qin, Tiejun / Xu, Zefeng / Qu, Shiqiang / Pan, Lijuan / Cai, Wenyu / Liu, Jinqin / Wang, Huijun / Sun, Qi et al. | 2021
- i
-
Cover ImageMpakou, Vassiliki / Spathis, Aris / Bouchla, Anthi / Tsakiraki, Zoi / Kontsioti, Frieda / Papageorgiou, Sotirios / Bazani, Efthymia / Gkontopoulos, Konstantinos / Thomopoulos, Thomas / Glezou, Irene et al. | 2021
-
ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR NON‐HODGKIN’S LYMPHOMA IN SWITZERLAND. 35 YEARS OF EXPERIENCE 1985‐2020. FOR SBST WORKING GROUPNabergoj, M. / Grandjean, B. / Stakia, P. / Stern, A. / Medinger, M. / Baldomero, H. / Masouridi‐Levrat, S. / Dantin, C. / Rovo, A. / Ritter, K. et al. | 2021
-
SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE, ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE UKRAINIAN LYMPHOMA REGISTRYSkrypets, T. / Stepanishyna, Y. / Galli, G. R. / Manni, M. / Hubareva, A. / Tytorenko, I. / Martynchyk, A. / Aleksik, O. / Shudrak, N. / Pastushenko, Y. et al. | 2021
-
IMPACT OF RITUXIMAB ON TREATMENT OUTCOMES OF PATIENTS WITH ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA; A POPULATION‐BASED ANALYSISMeeuwes, F. O. / Brink, M. / van der Poel, M. W.M. / Kersten, M. J. / Wondergem, Mariël. / Mutsaers, P. G.N.J. / Böhmer, L. H. / Woei‐A‐Jin, S. / Visser, O. / Oostvogels, R. et al. | 2021
-
KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88MT LYMPHOMA MODELSMayo, M / Karnik, R / Klaus, C / Sharma, K / McDonald, A / Walker, D. H / Weiss, M et al. | 2021
-
CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Lopez‐Girona, A / Groocock, L / Mo, Z / Narla, R. K / Janardhanan, P / Wood, S / Mendy, D / Barnes, L / Peng, S / Jankeel, D et al. | 2021
-
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMAHübel, K. / Scholz, C. W. / Luminari, S. / Salar, A. / Wahlin, B. E. / Gopal, A. K. / Bonnet, C. / Trneny, M. / Paneesha, S. / Manzke, O. et al. | 2021
-
OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTINGGodwin, J. E. / Mattar, B. / Maris, M. / Bachier, C. / Stevens, D. A. / Hoda, D. / Varela, J. C. / Cherry, M. / Fanning, S. / Essell, J. et al. | 2021
-
FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: TWO‐YEAR INTERIM RESULTS FROM THE FIGARO STUDYDimou, M / Huscher, D / Hermann, C / Pittrow, D / Speletas, M / Borte, M et al. | 2021
-
GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDYPaunescu, A.‐C. / Paget, J. / Bergman, C. Copie / Malak, S. / Le Gouill, S. / Ribrag, V. / Bouabdallah, K. / Sibon, D. / Rumpold, G. / Preau, M. et al. | 2021
-
MULTICENTER RETROSPECTIVE ANALYSIS OF RISK FACTORS FOR MORTALITY OF COVID‐19 INFECTION IN PATIENTS WITH LYMPHOMAKořen, J. / Steinerová, K. / Janíková, A. / Belada, D. / Hájková, B. / Krčméryová, M. / Hanáčková, V. / Vacková, B. / Jindra, P. / Osovská, M. et al. | 2021
-
POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIALBannerji, R. / Yuen, S. / Phillips, T. / Arthur, C. / Isufi, I. / Marlton, P. / Seymour, J. F. / Corradini, P. / Molinari, A. / Gritti, G. et al. | 2021
-
CLINICAL OUTCOMES IN PATIENTS RELAPSED/REFRACTORY AFTER ≥ 2 PRIOR LINES OF THERAPY FOR FOLLICULAR LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSISKanters, S / Kahl, B / Wiesinger, A / Gurung, B / Limbrick‐Oldfield, E. H / Sudhindra, A / Thornton Snider, J / Patel, A. R et al. | 2021
-
ACETYL‐COA ACETYLTRANSFERASE 1 ACTS AS A TUMOR SUPPRESSOR IN MALIGNANT TUMORSHu, X. / Zhang, Y. / Han, Y. / Zhang, X. / Tian, Z. / Wang, X. et al. | 2021
-
CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMASha, F. / Okwali, M. / Alperovich, A. / Caron, P. C. / Falchi, L. / Hamilton, A. / Hamlin, P. A. / Horwitz, S. M. / Joffe, E. / Kumar, A. et al. | 2021
-
CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDYBohers, E / Delfau‐Larue, M / Vercellino, L / Cottereau, A / Viennot, M / Viailly, P / Salles, G / Tilly, H / Damaj, G / Haioun, C et al. | 2021
-
CREBBP MEDIATED ACETYLATION OF KMT2D IN NORMAL AND TRANSFORMED GC B CELLSVlasevska, S. / Garcia‐Ibanez, L. / Duval, R. / Holmes, A.B. / Jahan, R. / Basso, K. / Dalla‐Favera, R. / Pasqualucci, L. et al. | 2021
-
IBRUTINIB FOLLOWED BY OFATUMUMAB CONSOLIDATION IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): GELLC‐7 TRIAL FROM THE SPANISH GROUP OF CLL (GELLC)Abrisqueta, P. / González‐Barca, E. / Ferrà, C. / Ríos, E. / Fernández de la Mata, M. / Delgado, J. / Andreu, R. / Án. Hernández‐Rivas, J. / José Terol, M. / González, M. et al. | 2021
-
OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED IN A BRAZILIAN PUBLIC CANCER CENTER – A REAL WORLD EXPERIENCE OF 809 PATIENTS IN A 11 YEAR PERIODBellesso, M / Pereira, J / Bassolli, L / Abdo, A. N. R / Junior, W. F. S / Velasques, R. D / Brandão, A. A. G. S / Melo, R. B / Lage, L. A. P. C / Maciel, F. V. R et al. | 2021
-
INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDYSharman, J. P. / Melear, J. M. / Yacoub, A. / Fanning, S. R. / Andorsky, D. J. / Nowakowski, G. S. / Rummel, M. J. / Lansigan, F. / Li, J. / Ahn, J. R. et al. | 2021
-
RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R‐NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL AND PATHOLOGICAL FACTORSCantò, C. / Pennese, E. / Di Nicola, M. / Ricciuti, G. / Restuccia, F. / Luciani, S. / Angrilli, F. et al. | 2021
-
EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR‐TCuadrado, M. / Menne, T. / Petrides, G. / Osborne, W. / Potter, V. / Benjamin, R. / Patten, P. / Yallop, D. / Sanderson, R. / Mulholland, N. et al. | 2021
-
SPLENIC INCREASED 18F‐FDG UPTAKE IN PET SCAN PERFORMED FOLLOWING TREATMENT WITH PEG‐GCSF LIPEFILGASTRIMFe', A. / Cimminiello, M. / Nicoletti, A. / Matturro, A. / Coralluzzo, G. / Pascale, S. P. / Nuccorini, R. / Fabio, L. / Mancino, S. / Cavallo, T. et al. | 2021
-
HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTINZinzani, P. L. / Raut, M. / Saretsky, T. / Ramchandren, R. / Santoro, A. / Paszkiewicz‐Kozik, E. / Gasiorowski, R. / Johnson, N. A. / de Oliveira, J. S. R. / Buccheri, V. et al. | 2021
-
LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMIMinoia, C. / Gerardi, C. / Allocati, E. / De Sanctis, V. / Franceschetti, S. / Viviani, S. / Annunziata, M. A. / Bari, A. / Skrypets, T. / Oliva, S. et al. | 2021
-
PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIALPavlovsky, A. / Fiad, L. / Fernandez, I. / Prates, V. / Kurgansky, N. / Cerutti, A. / Sackman, F. / Negri, F. / Zoppegno, L. / Negri, P. et al. | 2021
-
MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMASantarsieri, A. / Sturgess, K. / Brice, P. / Menne, T. F. / Osborne, W. / Creasey, T. / Ardeshna, K. M. / Behan, S. / Bhuller, K. / Booth, S. et al. | 2021
-
MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMAAbramson, J. S. / Bengston, E. M. / Redd, R. / Barnes, J. A. / Takvorian, T. / Sokol, L. / Lansigan, F. / Armand, P. / Shah, B. / Jacobsen, E. et al. | 2021
-
OUTCOMES AFTER INITIAL REFUSAL OF CURATIVE TREATMENT IN PATIENTS WITH HODGKIN LYMPHOMA IN BRITISH COLUMBIAChahal, M. / Jiang, A. / Hayden, A. / Savage, K. / Villa, D. / Scott, D. / Gerrie, A. / Lo, A. / Chan, M. / Pickles, T. et al. | 2021
-
TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMAMarra, A. / Venanzi, A / Schiavoni, G. / Milner, S. G. / Limongello, R. / Santi, A. / Pettirossi, V. / Ultimo, S. / Tasselli, L. / Pucciarini, A. et al. | 2021
-
MICROENVIRONMENT IMMUNE CELLS IN BONE MARROW AND LYMPH NODE MEASURED BY FLOW CYTOMETRY CAN PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMAKorin, L / Cranco, S / Fuente, M. L / Ochoa, P / Vitriu, A / Babuin, E / Diaz Couselo, F / Novoa, A / Tempra, P / Venegas, M. B et al. | 2021
-
ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDYChiappella, A. / Carniti, C. / Re, A. / Castellino, C. / Evangelista, A. / Ciancia, R. / Orsucci, L. / Pinto, A. / Usai, S. V. / Arcari, A. et al. | 2021
-
PERIPHERAL T‐CELL LYMPHOMAS INVOLVING CENTRAL NERVOUS SYSTEM: A REPORT FROM THE CZECH LYMPHOMA STUDY GROUP REGISTRYMocikova, H. / Pytlik, R. / Benesova, K. / Janikova, A. / Duras, J. / Sykorova, A. / Steinerova, K. / Prochazka, V. / Campr, V. / Belada, D. et al. | 2021
-
EXPRESSION OF HUMAN LEUCOCYTE ANTIGENS GENETIC POLYMORPHISMS IN A CASE SERIES OF FIVE PATIENTS WITH SEQUENTIAL LYMPHOMASVerrou, E / Fylaktou, A / Diamanti, I / Tsirou, K / Triantafyllou, T / Sevastoudi, A / Tsinaris, Z / Grigoriadou, G. I / Konstantinidou, P / Gioula, G et al. | 2021
-
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDYLevy, M. Y. / Grudeva‐Popova, Z. / Trneny, M. / Jurczak, W. / Pylypenko, H. / Jagadeesh, D. / Andre, M. / Nasta, S. / Rechavi‐Robinson, D. / Toffanin, S. et al. | 2021
-
THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATIONAl‐Sawaf, O. / Robrecht, S. / Stumpf, J. / Fink, A.‐M. / Ritgen, M. / Johansson, P. / Tausch, E. / Hoechstetter, M. / Staber, P. / Jäger, U. et al. | 2021
-
ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMASehn, L. H. / Kahl, B. / Matasar, M. / Lentz, G. / Izutsu, K. / Zhao, W. / Tao, L. / Calvo, R. / Zinzani, P. L. et al. | 2021
-
COPANLISIB IN COMBINATION WITH RITUXIMAB‐BENDAMUSTINE IN PATIENTS WITH RELAPSED‐REFRACTORY DLBCL: A MULTICENTRIC PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMINovo, M. / Castellino, A. / Chiappella, A. / Ciccone, G. / Balzarotti, M. / Di Rocco, A. / Spina, M. / Vitolo, U. et al. | 2021
-
DEFINING ULTRA‐HIGH‐RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY)Thieblemont, C / Deux, J.‐F / Vercellino, L / Chartier, L / Casasnovas, O / Judet, A / Baud, V / Tilly, Hervé / Cottereau, A.‐S / Meignan, M et al. | 2021
-
EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMABücklein, V. / Blumenberg, V. / Ackermann, J. / Frölich, L. / Winkelmann, M. / Schmidt, C. / Rejeski, K. / Ruzicka, M. / Müller, N. / von Baumgarten, L. et al. | 2021
-
CYTIDINE DEAMINASES SHAPE THE GENOME OF GERMINAL CENTER B CELL DERIVED LYMPHOMARen, M. / Sidiropoulou, E. / Tasakis, R. N. / Donato, E. / Gonzalez‐Menendez, I. / Busse, C. E / Luck, T. J / Dolnik, A. / Bullinger, L. / Trumpp, A. et al. | 2021
-
IMPAIRED HUMORAL RESPONSE IN LYMPHOMA PATIENTS SURVIVING THE ACUTE PHASE OF COVID‐19Cattaneo, C. / Cancelli, V. / Pagani, C. / Ogna, A. / Tucci, A. / Rossi, G. / Quaresima, V. / Sotttini, A. / Dobbs, K. / Notarangelo, L. D. et al. | 2021
-
CLINICAL IMPACT OF T‐CELL RECEPTOR REPERTOIRE DIVERSITY IN PATIENTS WITH LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATIONJørgensen, G. Ø / Favero, F / Schmidt Jespersen, J / Tulstrup, M. R / Rodriguez‐Gonzalez, F. G / Nielsen, A. F / Sørensen, B / Ebbesen, L. H / Bæch, J / Haastrup, E. K et al. | 2021
-
INFLUENCE OF ACTIVE CARDIOMONITORING ON THE OVERALL SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOLEUKEMIA RECEIVING IBRUTINIBEmelina, E / Gendlin, G / Nikitin, I et al. | 2021
-
CLONAL HEMATOPOIESIS IS ASSOCIATED WITH INFERIOR PROGNOSIS IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTSBoegeholz, J / Alig, S / Sworder, B / Macaulay, C / Craig, A / Dührsen, U / Hüttmann, A / Miklos, D / Frank, M / Diehn, M et al. | 2021
-
OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDYGhione, P. / Ghesquieres, H. / Bobillo, S. / Patel, A. R. / Kanters, S. / Deighton, K. / Dong, H. / Yang, Y. / Ma, L. / Limbrick‐Oldfield, E. H. et al. | 2021
-
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDYLeppä, S / Jørgensen, J / Karjalainen‐Lindsberg, M‐L / Beiske, K / Nørgaard, P / Drott, K / Pasanen, A / Karihtala, K / Mannisto, S / Wold, B et al. | 2021
-
OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDYMuntañola, A. / Magnano, L. / Mercadal, S. / Huguet, M. / Bobillo, S. / Bastos‐Oreiro, M. / Jiménez‐Ubieto, A. / Rovira, J. / Rivero, A. / Alcoceba, M. et al. | 2021
-
BENDAMUSTINE‐RITUXIMAB COMPARED TO RITUXIMAB‐CHOP/CVP FOR TREATMENT OF PATIENTS WITH INDOLENT LYMPHOMA IN ONTARIO: A POPULATION‐BASED STUDYSuleman, A. / Aktar, S. / Liu, N. / Chan, K. / Cheung, M. / Prica, A. et al. | 2021
-
MAINTENANCE THERAPY AFTER R‐BENDAMUSTINE VS R‐CHOP IN FIRST‐LINE TREATMENT OF LOW‐GRADE FOLLICULAR LYMPHOMA: A MULTICENTRE, RETROSPECTIVE GELTAMO STUDYBastos‐Oreiro, M. / Gutierrez, A. / Martín, R. / Cabero, A. / Navarro, B. / Jimenez‐Unieto, A. / Alonso, C. / Gonzalez de Villambrosia, S. / Córdoba, R. / Perez de Oteyza, J. et al. | 2021
-
REAL WORLD OUTCOME IN MANTLE CELL LYMPHOMA: A FRENCH RETROSPECTIVE STUDY IN ELDERLY PATIENTS BETWEEN 2005 AND 2018Branco, B / Bories, P / Ysebaert, L / Laurent, C / Cabarrou, B / Botin / Leveneur, Y / Ghenim, L / Gaspard, M.‐H / Hess, N et al. | 2021
-
VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDYAl‐Sawaf, O / Zhang, C / Lu, T / Liao, M. Z / Panchal, A / Robrecht, S / Ching, T / Tandon, M / Fink, A.‐M / Tausch, E et al. | 2021
-
CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMAManji, F. / Bhella, S. / Kridel, R. / Kukreti, V. / Kuruvilla, J. / Prica, A. / Crump, M. et al. | 2021
-
OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA AFTER HIGH‐DOSE METHOTREXATE FOLLOWED BY CONSOLIDATION WHOLE‐BRAIN RADIOTHERAPY AND CYTARABINEPiriyakhuntorn, P / Rattanathammethee, T / Hantrakool, S / Chai‐Adisaksopha, C / Rattarittamrong, E / Tantiworawit, A / Norasetthada, L et al. | 2021
-
EVALUATION OF FOUR PROGNOSTIC INDEXES IN FIRST LINE FOLLICULAR LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPYFernández‐Rodríguez, C. / Diez‐Feijoo Varela, R. / Sanchez‐Gonzalez, B. / Bento, L. / Fernández‐Ibarrondo, L. / Gibert, J. / Lafuente, M. / Rodriguez‐Sevilla, J. J. / Pinzón, S. / Espinet, B. et al. | 2021
-
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON‐1 STUDYCrosswell, H. E / LaCasce, A. S. / Bartlett, N. L / Straus, D. J / Savage, K. J / Zinzani, P. L / Collins, G. P / Fanale, M. A / Fenton, K / Dong, C et al. | 2021
-
A UK POPULATION‐BASED STUDY OF NON‐HODGKIN LYMPHOMA IN TEENAGERS AND YOUNG ADULTS (TYA) ‐ INCIDENCE, TREATMENT AND OUTCOMESCarr, R / Davies, A / Uttenthal, B / Lamb, M / Fidalgo, J / Carpenter, B et al. | 2021
-
COMBINATION OF DECITABINE AND MODIFIED DHAP REGIMEN: A POTENTIAL SALVAGE REGIMEN FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA AFTER SECOND‐LINE TREATMENT FAILUREHu, J / Wang, X / Zhang, M / Chen, Q / Zhang, X et al. | 2021
-
PIXANTRONE (PIX) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). REAL LIFE EXPERIENCE IN 27 PATIENTSGreco, A / Tonialini, L / Scalzulli, P. R / De Santis, G / Prete, E / La Rosa, E / Cascavilla, N / Tarantini, G / Pavone, V et al. | 2021
-
GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMABonfiglio, F. / Bruscaggin, A. / Guidetti, F. / Terzi di Bergamo, L. / Faderl, M. / Spina, V. / Condoluci, A. / Bonomini, L. / Forestieri, G. / Koch, R. et al. | 2021
-
NONINVASIVE DETECTION, CLASSIFICATION, AND RISK STRATIFICATION OF PRIMARY CNS LYMPHOMAS BY CTDNA PROFILINGMutter, J. A. / Alig, S. / Lauer, E. M. / Esfahani, M. S. / Mitschke, J. / Kurtz, D. M. / Olsen, M. / Liu, C. L. / Jin, M. C. / Bleul, S. et al. | 2021
-
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDYAl‐Sawaf, O. / Zhang, C. / Robrecht, S. / Tandon, M. / Panchal, A. / Fink, A.‐M. / Tausch, E. / Ritgen, M. / Kreuzer, K.‐A. / Kim, S. et al. | 2021
-
LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIALBagot, M. / Kim, Y. / Zinzani, P. L. / Dalle, S. / Beylot‐barry, M. / Ortiz‐Romero, P. L / Cambalia, A. / Dereure, O. / Mortier, L. / Jacobsen, E. et al. | 2021
-
THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTSHorwitz, S. M. / Moskowitz, A. J. / Mehta‐Shah, N. / Jacobsen, E. D. / Khodadoust, M. S. / Ganesan, N. / Drill, E. / Hancock, H. / Davey, T. / Myskowski, P. et al. | 2021
-
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMAKim, W.‐S. / Yoon, D.‐H. / Song, Y. / Koh, Y. / Cao, J. / Ji, D. / Yang, H. / Eom, H.‐S. / Jing, H. / Kwak, J.‐Y. et al. | 2021
-
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDYWang, M. / Rule, S. / Zinzani, P. L. / Goy, A. / Casasnovas, O. / Smith, S. D. / Damaj, G. / Doorduijn, J. K. / Lamy, T. / Morschhauser, F. et al. | 2021
-
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIALBologna, S / Vander Borght, T / Briere, J / Ribrag, V / Damaj, G. L / Thieblemont, C / Feugier, P / Peyrade, F / Lebras, L / Coso, D et al. | 2021
-
LONG TERM OUTCOMES OF EARLY STAGE PRIMARY GASTRIC DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTI‐CENTRE RETROSPECTIVE STUDYSmith, C. D. / Chin, Y. S. / Gupta, S. A. / Thompson, S. R. et al. | 2021
-
EVALUATION OF RESPONSE TO THE FIRST‐LINE THERAPY OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA BASED ON INTERIM PET‐CT AT A PRIVATE BRAZILIAN INSTITUTIONDe Almeida, J. M. / Alves, A. et al. | 2021
-
OLDER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): REAL WORLD (RW) OUTCOMES OF POST‐INDUCTION THERAPY IN THE MODERN ERADavid, K. A. / Sundaram, S. / Kim, S.‐H. / Vaca, R. / Lin, Y. / Singer, S. / Malecek, M.‐K. / Carter, J. / Zayac, A. / Kim, M. S. et al. | 2021
-
CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMASpina, V. / Pirosa, M. C. / Bruscaggin, A. / Condoluci, A. / Pini, K. / Forestieri, G. / Zangrilli, I. / di Trani, M. / Kurlapski, M. / Moccia, A. et al. | 2021
-
INTRATUMORAL T‐CELLS HAVE A DIFFERENTIAL IMPACT ON FDG‐PET PARAMETERS IN FOLLICULAR LYMPHOMANath, K. / Law, Soi‐C. / Talaulikar, D. / Sabdia, M. B. / Gunawardana, J. / de Long, L. M. / Shanavas, M. / Tsang, H. / Tobin, J. W. / Halliday, S.‐J. et al. | 2021
-
DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMIMerli, M. / Rattotti, S. / Spina, M. / Re, F. / Motta, M. / Piazza, F. / Orsucci, L. / Ferreri, Andrés J.M. / Perbellini, O. / Dodero, A. et al. | 2021
-
PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)Conconi, A. / Vannata, B. / Janikova, A. / Ramirez, A. / Bodoni, C. Lobetti / Nowakowski, G. / Mian, M. / Ferreri, Andrés J.M. / Ryan, G. / Pangalis, G. A. et al. | 2021
-
EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIALSchuster, S. J. / Dickinson, M. / Dreyling, M. / Martinez‐Lopez, J. / Kolstad, A. / Butler, J. / Ghosh, M. / Popplewell, L. / Chavez, J. C. / Bachy, E. et al. | 2021
-
PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMAMead, M. D. / Popplewell, L. L. / Subklewe, M. / Ghobadi, A. / Kuruvilla, J. / Kimball, A. / Tuglus, C. / Agarwal, S. / Stieglmaier, J. et al. | 2021
-
LYMPHOMA TREATMENT IN DEVELOPING COUNTRIESBiondi, A. et al. | 2021
-
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)Salles, G / Goswami, B / Bagnardi, V / Dey, D / Winderlich, M / Ambarkhane, S / Huang, D / Nowakowski, G. S et al. | 2021
-
A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF THE TOXICITY OF HIGH‐DOSE METHOTREXATE (HDMTX) ADMINISTERED ON THE FIRST DAY OF (R)CHOP IN AGGRESSIVE NONHODGKIN LYMPHOMAS (ANHLS)Fleming, M / Huang, Y / Dotson, E / Bond, D. A / Reneau, J / Epperla, N / Alinari, L / Brammer, J / Christian, B / Baiocchi, R. A et al. | 2021
-
MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE‐BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7‐YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIALMutter, J. A. / Alig, S. / Lauer, E. M. / Esfahani, M. S. / Mitschke, J. / Kurtz, D. M. / Olsen, M. / Liu, C. L. / Jin, M. C. / Bleul, S. et al. | 2021
-
OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDYCamus, V. / Rossi, C. / Sesques, P. / Lequesne, J. / Tonnelet, D. / Haioun, C. / Durot, E. / Willaume, A. / Gauthier, M. / Moles‐Moreau, Marie‐P. et al. | 2021
-
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)Al‐Sawaf, O. / Esfahani, M. S. / Zhang, C. / Tausch, E. / Schilhabel, A. / Eichhorst, B. / Stilgenbauer, S. / Hallek, M. / Alizadeh, A. A. / Kurtz, D. M. et al. | 2021
-
REAL WORLD APPLICATION OF R‐CHOP FOR DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN BELGIUM AND ITS IMPACT ON SURVIVALDaneels, W / Rosskamp, M / Macq, G / Saadoon, E / Degeyndt, A / Offner, F / Antoine‐Poirel, H et al. | 2021
-
PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENTFerreri, A. J.M. / Tarantino, V. / Cabras, G. / Ferrara, F. / Zinzani, P. L. / Arcaini, L. / Castellino, A. / Tucci, A. / Cocito, F. / Davies, A. et al. | 2021
-
TRACKING THE EVOLUTION OF UNTREATED HIGH‐INTERMEDIATE/HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA BY CIRCULATING TUMOR DNAZhang, S / Zhang, T / Song, Z / Li, W / Yu, J / Zhao, J / Zhou, S / Qian, Z / Li, L / Qiu, L et al. | 2021
-
PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH‐DOSE METHOTREXATE (R2‐MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMAZhang, Y. / Wang, W. / Zhao, D. / Zhang, W. / Zhou, D. et al. | 2021
-
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)Zinzani, P. L. / Carlo‐Stella, C. / Hamadani, M. / Herrera, A. F. / Ansell, S. M. / Radford, J. / Maddocks, K. / Kline, J. / Savage, K. J. / Bartlett, N. L. et al. | 2021
-
LENALIDOMIDE AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDYZhang, Y. / Zhang, X. / Zou, Dong‐m. / Zhang, L. / Zhang, Mei‐f. / Zhou, D. / Zhang, W. et al. | 2021
-
PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: INTENSIFIED REGIMENS DO NOT IMPROVE OUTCOMES AS COMPARED TO RCHOP IN A RESOURCE‐CONSTRAINED SETTINGVelasques, R. D. / Silva, W. F. / Bellesso, M. / Rocha, V. / Pereira, J. et al. | 2021
-
HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR IN DLBCL PATIENTS TREATED BY R‐CHOP, INDEPENDENT FROM TMTV AND PS –FROM THE REMARC STUDYDeux, J.‐F. / Meignan, M. / Chartier, L. / Judet, A. / Vercellino, L. / Casasnovas, O. / Baud, V. / Tilly, H. / Cottereau, A.‐S. / Thieblemont, C. et al. | 2021
-
T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIAAmaador, K / Martens, A. W. J / de Boer, R / Rietveld, J. M / Eldering, E / Kersten, M. J / Kater, A. P / Vos, J. M. I / Tonino, S. H et al. | 2021
-
DEEP LEARNING TO PREDICT THE EFFECT OF DRUGS IN PATIENTS WITH LYMPHOMA BASED ON CELL LINE DATAChebanov, D. K. / Mikhaylova, I. N. / Tatevosova, N. S. et al. | 2021
-
THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL)Merli, F. / Tucci, A. / Arcari, A. / Rigacci, L. / Cavallo, F. / Cabras, G. / Alvarez, I. / Fabbri, A. / Re, A. / Ferrero, S. et al. | 2021
-
ARTIFICIAL INTELLIGENCE AND PATHOLOGYBrousset, P et al. | 2021
-
THE PATIENT AND CARER EXPERIENCE OF CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY FOR RELAPSED/REFRACTORY B‐CELL LYMPHOMA AT A UK REGIONAL CENTREStenson, C. / Menne, T. / Osborne, W. / Publicover, A. / Kennedy, H. / Shaw, J. / Dewhurst, F. / Stocker, R. / Vidrine, J. et al. | 2021
-
PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMALebel, E. / Jain, M. D. / Prica, A. / Kukreti, V. / Kridel, R. / Laister, R. C. / Meng, L. / Delabie, J. / Weiss, J. / Panzarella, T. et al. | 2021
-
USE OF DEEP LEARNING TO ANALYSE AND EXPLOIT MOLECULAR DATALandau, D.A et al. | 2021
-
REAL WORLD OUTCOMES AND RESPONSES TO SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTRE UK STUDYShotton, R. / Kirkwood, A. A. / Northend, M. / Fathoala, D. / Burton, K. / Ferguson, G. / Aiken, L. / Shrubsole, C. / Henry, L. / Owen, M. et al. | 2021
-
CLINICAL, LABORATORY, IMAGING FINDINGS AND TREATMENT OF 60 CASES WITH CASTLEMAN'S DISEASESiyu, Q. / Xudong, Z. et al. | 2021
-
9P GAIN PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX +/‐ ATEZOLIZUMAB. ARGO: A RANDOMISED PHASE II STUDYDavies, A / McKay, P / Osborne, W / Stanton, L / Tansley‐Hancock, O / Lawrence, M / Mercer, K / Allen, A / Pottinger, B / Zhelyazkova, A et al. | 2021
-
TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMAChoi, J. W / Corcoran, S / Wang, B / Häupl, Björ / Ceribelli, M / Huang, D. W / Wright, G. W / Shaffer, A. L III / Phelan, J. D / Scheich, S et al. | 2021
-
PERIPHERAL T‐CELL LYMPHOMA: MOLECULAR PROFILING DISTINGUISHES SUBCLASSES, RECOGNIZES THE TUMOR ARCHITECTURE AND IDENTIFIES PROGNOSTIC MARKERSRodríguez, M / Tomás‐Roca, L / Alonso‐Alonso, R / Manso‐Alonso, R / Cereceda, L / Borregón, J / Villaescusa, T / Raúl Córdoba / Sánchez‐Beato, M / Fernández‐Miranda, I et al. | 2021
-
GLYCOPROTEIN PTGDS ACTS AS A POTENTIAL TARGET IN DIFFUSE LARGE B‐CELL LYMPHOMA BY REGULATING MYH9‐WNT‐β‐CATENIN/STAT3 AXISHu, S / Zhou, X / Ren, S / Cai, Y / Liu, J / Han, Y / Zhao, Y / Yang, J / Wang, X et al. | 2021
-
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTSDepaus, J / Wagner‐Johnston, N / Zinzani, P. L / Phillips, T. J / Maly, J / Ferrari, S / Bachy, E / Bryan, L. J / Delwail, V / Janakiram, M et al. | 2021
-
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUPAl Tabaa, Y. / Casasnovas, O. / Baillet, C. / Bachy, E. / Virelizier, E. Nicolas / Schiano de Colella, J. M. / Bailly, C. / Kanoun, S. / Guidez, S. / Gyan, E. et al. | 2021
-
IMMUNOHISTOCHEMICAL AND HISTOPATHOLOGICAL STUDY FOR THE DIAGNOSIS AND CLASSIFICATION OF LYMPHOMASJiménez Galainena, J. J / Lamadrid García, J / Gutiérrez Aleaga, Z / Amigó de Quesada, M / Nazario Dolz, M / Heredia Manzano, L / Gámez Pérez, E / Marcial Martínez, W / Columbié Molina, A / Gracia Medina, E et al. | 2021
-
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)Morschhauser, F. / Nowakowski, G. S. / Cartron, G. / Kesanakurthy, V. / Gkasiamis, A. / Patah, P. / Delarue, R. / Wang, T. / Li, J. / Xian, D. et al. | 2021
-
SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDYJaeger, U. / Worel, N. / McGuirk, J. P. / Riedell, P. A. / Fleury, I. / Borchmann, P. / Du, Y. / Abdelhady, A. M. / Han, X. / Martinez‐Prieto, M. et al. | 2021
-
A SINGLE‐ARM, OPEN‐LABEL, PILOT TRIAL OF AUTOLOGOUS CD7‐CAR‐T CELLS FOR CD7 POSITIVE RELAPSED AND REFRACTORY T‐LYMPHOBLASTIC LEUKEMIA/LYMPHOMAZhang, M. / Fu, X. / Meng, H. / Chen, D. / Wang, M. / Zhang, L. / Li, L. / Li, X. / Wang, X. / Sun, Z. et al. | 2021
-
QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS TREATED WITH ANTI‐CD19 CAR T‐CELLSGuidetti, A. / Dodero, A. / Argiroffi, G. / Verderio, P. / Lorenzoni, A. / Chiappella, A. / Carniti, C. / Seregni, E. / Pizzamiglio, s. / Alessi, A. et al. | 2021
-
EFFICACY AND SAFETY OF DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: A SERIES OF COCHRANE REVIEWSHirsch, C. / Piechotta, V. / Langer, P. / Scheid, C. / John, L. / Skoetz, N. et al. | 2021
-
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UPJanssens, A / Snauwaert, S / Bron, D / Berneman, Z / Offner, F / Van Bogaert, C / De Beleyr, B / Smet, A / Nielsen, L / Wapenaar, R et al. | 2021
-
INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY| 2021
-
THE ARCHITECTURE OF LIQUID BIOPSY RESEARCH FOR LYMPHOMA MONITORING| 2021
-
TEMOZOLOMIDE, ETOPOSIDE, DOXIL, DEXAMETHASONE, IBRUTINIB AND RITUXIMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CLINICAL PRACTICERingeleviciute, U / Cernauskiene, S / Zucenka, A / Pileckyte, R / Griskevicius, L et al. | 2021
-
CURRENT STATUS AND CHALLENGES IN DIAGNOSIS OF CHILDHOOD NHLKlapper, W et al. | 2021
-
SALVAGE RADIOTHERAPY ASSOCIATES WITH DURABLE RESPONSE FOR A SUBSET OF PATIENTS WITH LIMITED STAGE REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAMiller, J. H / Gilbertson, M / MacManus, M. P / Wirth, A / Opat, S. S / Gregory, G. P et al. | 2021
-
MOLECULAR SUBCLUSTERS OF FOLLICULAR LYMPHOMA: A REPORT FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORKCrouch, S. / Painter, D. / Barrans, S. / Roman, E. / Beer, P. / Lacy, S. / Cooke, S. / Webster, N. / Glover, P. / van Hoppe, S. et al. | 2021
-
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDYJurczak, W. / Shah, N. N. / Lamanna, N. / Eyre, T. A. / Woyach, J. / Lech‐Maranda, E. / Wierda, W. G. / Lewis, D. / Thompson, M. C. / Wang, D. et al. | 2021
-
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUPBröckelmann, P. J. / Müller, H. / Gillessen, S. / Yang, X. / Koeppel, L. / Pilz, V. / Marinello, P. / Kaskel, P. / Raut, M. / Fuchs, M. et al. | 2021
-
BURDEN OF MULTIPLE MYELOMA IN CHINA: AN ANALYSIS OF THE GLOBAL BURDEN OF DISEASE, INJURIES, AND RISK FACTORS STUDY 2019Liu, W. / Liu, J. / Mi, L. / Cai, C. / Gong, T. / Ma, J. / Wang, L. et al. | 2021
-
PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILEQuerfeld, C. S. / Tsai, N.‐C. / Palmer, J. / Martinez, X. / Abdulla, F. / Wu, X. / Rosen, S. T. / Zain, J. et al. | 2021
-
ROMIDEPSIN AND CARFILZOMIB IN RELAPSED / REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH ASSESSMENT OF H23B AS A PREDICTIVE BIOMARKER – THE UK NCRI SEAMLESS PHASE 1/2 ROMICAR TRIALCollins, G. P. / Booth, S. / Cherrill, L. R. / Slade, D. / Morland, C. / Hopkins, L. / Nagy, E. / Linton, K. / Fox, C. P. / Lewis, D. et al. | 2021
-
SINTILIMAB PLUS CHIDAMIDE FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM, PHASE IB/II TRIAL (SCENT)Huang, H. / Gao, Y. / Wang, X. / Bai, B. / Zhang, L. / Xiao, Y. / Liu, X. / Li, W. / Cai, Q. / Li, Z. et al. | 2021
-
TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIESCheah, C. Y / Jurczak, W / Lasica, M / Wickham, N / Wróbel, T / Walewski, J / Yannakou, C. K / Cheung, S / Lewis, K. L / Długosz‐Danecka, M et al. | 2021
-
FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCLBelada, D / Kopeckova, K / Bergua Burgues, J. M / André, M / Pérez Persona, E / Pichler, P / Klöpfer, P / Brackertz, B / Lohrmann, E / Lahiry, A et al. | 2021
-
AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIESJoffe, E. / Ramchandren, R. / Nowakowski, G. / Rosenthal, A. / Tun, H. W. / Lunning, M. / Mead, M. D. / Martinez, E. / von Roemeling, R. / Leslie, L. et al. | 2021
-
EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGNChoquet, S. / Pérez‐Simón, J. A. / Worel, N. / Chaganti, S. / Dinavahi, R. / Guzman‐Becerra, N. / Navarro, W. / Sun, Y. / Gamelin, L. et al. | 2021
-
CCL2‐CCR2 AXIS SIGNALING PROMOTES DIFFUSE LARGE B‐CELL LYMPHOMA CELL SURVIVAL AND INVASIONYan‐Li, L. et al. | 2021
-
OBINUTUZUMAB CAN BE ADMINISTERED AS A 90‐MINUTE SHORT‐DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: GAZELLE END OF INDUCTION ANALYSISHübel, K. / Buchholz, T. A. / Izutsu, K. / Ishikawa, T. / Fogliatto, L. M. / Vorozheikina, E. / Klingbiel, D. / Pokala, S. / Tomiczek, M. / Parreira, J. et al. | 2021
-
MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSISFrustaci, A. M. / Tedeschi, A. / Zinzani, P. L. / Pietrasanta, D. / Coscia, M. / Zenz, T. / Motta, M. / Gaidano, G. / Scarfò, L. / Deodato, M. et al. | 2021
-
EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDYVisentin, A. / Mauro, F. R. / Cibien, F. / Vitale, C. / Reda, G. / Fresa, A. / Ciolli, S. / Pietrasanta, D. / Marchetti, M. / Murru, R. et al. | 2021
-
SAFETY OF SAME DAY HD‐MTX WITH INDUCTION THERAPY FOR DLBCL WITH CONCURRENT CNS DISEASE OR AS PROPHYLAXIS FOR HIGH RISK OF CNS RELAPSEBarlow, B. / Bodine, C. D. / Hatic, H. / Goyal, G. / Mehta, A. / Narkhede, M. et al. | 2021
-
R‐CODOX‐M/R‐IVAC IN HIGH RISK AND MYC MUTATED DIFFUSE LARGE B CELL LYMPHOMA‐ A SINGLE CENTRE RETROSPECTIVE STUDYBeverstock, S. L. / Scott, F. M. et al. | 2021
-
ZANUBRUTINIB, LENALIDOMIDE PLUS R‐CHOP (ZR2‐CHOP) AS THE TREATMENT FOR DIFFUSED LARGE B‐CELL LYMPHOMA (DLBCL)Zhu, H. / Sha, Y. / Wu, W. / Chen, R. / Yang, Y. / Qiu, J. / Mi, H. / Peng, C. / Ding, C. / Wang, Z. et al. | 2021
-
ESA VERSUS MESA WITH SANDWICHED RADIOTHERAPY IN PATIENTS WITH EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA: A MULTICENTRE, RANDOMISED, PHASE 3, NON‐INFERIORITY TRIALZhong, H.‐J. / Cheng, S. / Zhang, X. / Xu, B. / Chen, J.‐Y. / Jiang, X.‐F. / Hu, Y. / Cui, G.‐H. / Wei, J.‐Y. / Qian, W.‐B. et al. | 2021
-
A SIMPLE EPIGENETIC SIGNATURE DEFINES TWO BIOLOGIC GROUPS OF MANTLE CELL LYMPHOMABühler, M. M. / Kulis, M. / Duran‐Ferrer, M. / Clot, G. / Nadeu, F. / Navarro, A. / López, C. / Giné, E. / Beà, S. / Campo, E. et al. | 2021
-
BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)Massaro, F. / Pavone, V. / Stefani, P. M. / Botto, B. / Pulsoni, A. / Patti, C. / Cantonetti, M. / Visentin, A. / Scalzulli, P. R. / Rossi, A. et al. | 2021
-
COPY NUMBER VARIATION ANALYSIS IDENTIFIES DISTINCT GENOMIC FEATURES IN ADULT BURKITT LYMPHOMADreval, K. / Thomas, N. / Gerhard, D. S. / Hilton, L. K. / Wong, J. / Abramson, J. S. / Bartlett, N. L. / Bethony, J. / Bowen, J. / Bryan, A. C. et al. | 2021
-
KEY GENETIC AND MOLECULAR ABERRATIONS IDENTIFIED IN BOTH ADULT AND EBV‐POSITIVE BURKITT LYMPHOMA PATIENTSOrem, J. / Martin, M.‐R. / Mbulaiteye, S. M. / Mullighan, C. G. / Mungall, A. J. / Mungall, K. / Namirembe, C. / Noy, A. / Petrello, H. / Ogwang, M. D. et al. | 2021
-
LIFE AFTER CAR‐T CELLS: A PROSPECTIVE STUDY EVALUATING THE PERSONAL, SOCIAL AND PROFESSIONAL OUTCOMES AFTER CAR‐T CELL THERAPY IN LYMPHOMA PATIENTSMoignet, A. / Anota, A. / Colin, F. / Cherel, L. / Lorne, B. / Lamy, T. / De Guibert, S. / Ysebaert, L. / Houot, R. et al. | 2021
-
LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIALCamus, V. / Belot, Aurél. / Oberic, L. / Sibon, D. / Ghesquières, H. / Thieblemont, C. / Fruchart, C. / Casasnovas, O. / Michot, Jean‐M. / Molina, T. J. et al. | 2021
-
IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMATun, A. M / Wang, Y / Maliske, S / Farooq, U / Micallef, I. N / Inwards, D. J / Porrata, L. F / Ansell, S. M / Rosenthal, A. C / Kharfan‐Dabaja, M et al. | 2021
-
AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMITucci, A / Musuraca, G / Cavallo, F / Zilioli, V. R / Zanni, M / Pelliccia, S / Mannina, D / Michieli, M / Vallisa, D / Tani, M et al. | 2021
-
A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)Kim, W. S. / Rai, S. / Ando, K. / Choi, I. / Izutsu, K. / Tsukamoto, N. / Yokoyama, M. / Tsukasaki, K. / Kuroda, J. / Ando, J. et al. | 2021
-
SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0Federico, M / Chiattone, C. S / Prince, H. M / Pavlovsky, A / Manni, M / Civallero, M / Skrypets, T / De Souza, C. A / Hawkes, E. A / Fiad, L et al. | 2021
-
CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECTCollinge, B. J. / Hilton, L. K / Wong, J. / Ben‐Neriah, S. / Rushton, C. K. / Slack, G. W. / Farinha, P. / Cook, J. R. / Ott, G. / Rosenwald, A. et al. | 2021
-
MUTATIONAL ANALYSIS OF THE DIFFERENT NODAL PERIPHERAL T‐CELL LYMPHOMA SUBCLASSESTomas‐Roca, L / Rodriguez, M / Alonso‐Alonso, R / Cereceda, L / Rodriguez‐Pinilla, S. M / Borregón, J / Manso, R / Villaescusa, T / Córdoba, R / Sánchez‐Beato, M et al. | 2021
-
PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMABrown, F / Hwang, I / Sloan, S / Hinterschied, C / Helmig‐Mason, J / Long, M / Youssef, Y / Chan, W / Prouty, A / Chung, J et al. | 2021
-
ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMARibeiro, M. L / Reyes‐Garau, D / Vinyoles, M / Profitos‐Peleja, N / Santos, J. C / Armengol, M / Fernandez‐Serrano, M / Bech‐Serra, J. J / Blecua, P / Musulen, E et al. | 2021
-
ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMABooth, S. / Kirkwood, A. / Johnson, P. / Barrington, S. / Gallop‐Evans, E. / Peggs, K. / Warbey, V. / Burton, C. / Ardavan, A. / Phillips, B. et al. | 2021
-
BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE IN NEWLY DIAGNOSED PATIENTS WITH ADVANCED HODGKIN LYMPHOMA (SGN35‐027, TRIAL IN PROGRESS)Flinn, I. / Friedman, J. D. / Ho, L. / Lee, H. J. et al. | 2021
-
PROGNOSTIC VALUE OF APOLIPOPROTEIN A IN CHRONIC LYMPHOCYTIC LEUKEMIAYun, X / Zhang, Y / Sun, X / Hu, X / Zhang, H / Yin, Z / Zhang, X / Liu, M / Wang, X et al. | 2021
-
MUTATIONAL LANDSCAPE OF MARGINAL ZONE B‐CELL LYMPHOMAS OF VARIOUS ORIGIN: ORGANOTYPIC ALTERATIONS AND DIAGNOSTIC POTENTIAL FOR ASSIGNMENT OF ORGAN ORIGINDirnhofer, S / Vela, V / Juskevicius, D / Menter, T / Tzankov, A et al. | 2021
-
OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSISDreger, P. / Martus, P. / Holtick, U. / Ayuk, F. / Wagner‐Drouet, E. M. / Wulf, G. / Marks, R. / Penack, O. / Koenecke, C. / von Bonin, M. et al. | 2021
-
CARDIOTOXICITY RISK IN PATIENTS WITH NON‐HODGKIN LYMPHOMA RECEIVING EPOCH AFTER PRIOR ANTHRACYCLINE EXPOSUREBuege, M. J. / Dao, P. H. / Drill, E. / Horwitz, S. M. / LeVoir, A. / Pak, T. / Peterson, T. J. / Matasar, M. J. et al. | 2021
-
IMPACT OF THE COVID‐19 PANDEMIC ON THE DIAGNOSIS OF MATURE LYMPHOID NEOPLASMS IN BELGIUM: RESULTS FROM THE BELGIAN CANCER REGISTRYAntoine‐Poirel, H. / Calay, F. / Tambuyzer, T. / Denolf, P. / Van Eycken, L. et al. | 2021
-
PROGNOSTIC ROLE OF LESION DISSEMINATION FEATURE (DMAX) CALCULATED ON BASELINE PET/CT IN HODGKIN LYMPHOMADurmo, R / Ségolèn Cottereau, A / Rebaud, L / Nioche, C / Ruffini, A / Fioroni, F / Meignan, M / Buvat, I / Merli, F / Versari, A et al. | 2021
-
LONG TERM OUTCOMES OF GASTRIC MALT LYMPHOMA TREATED WITH RADIOTHERAPY: A MULTI‐CENTRE RETROSPECTIVE STUDYSmith, C / Gupta, S. A / Chin, Y. S / Thompson, S. R et al. | 2021
-
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)Batlevi, C. L. / Salles, G. / Tilly, H. / Chaidos, A. / McKay, P. / Phillips, T. / Assouline, S. / Campbell, P. / Ribrag, V. / Damaj, G. Laurent et al. | 2021
-
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIACondoluci, A. / Terzi‐di‐Bergamo, L. / Forestieri, G. / Moia, R. / Deambrogi, C. / Deodato, M. / Frustaci, A. M. / Merli, M. / Mattarucchi, R. / Autore, F. et al. | 2021
-
PROGNOSTIC IMPACT OF NUTRITIONAL STATUS ON DLBCL PATIENTSBarros Lima, C. / Marques, B. / Duarte, S. / Afonso, C. / Neves, D. / Lai, A. / Julião, M. / Ruzickova, L. / Carda, J. / Gomes, M. et al. | 2021
-
THE PRIMARY RESULTS OF THE EFFICACY OF UPFRONT HIGH‐DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR IV STAGE AND HIGH‐INTERMEDIATE/HIGH IPI RISK GROUPS DLBCLFilatova, L / Zyuzgin, I / Artemyeva, A / Motalkina, M / Chudinovskikh, Y / Volchenkov, S / Poliatskin, I / Cherkasova, E / Shalaev, S / Ishmatova, I et al. | 2021
-
THE ROLE OF MULTIPARAMETRIC FLOW CYTOMETRY IN DETECTING AND CHARACTERIZING GAMMA‐DELTA T‐CELL ENTITIES IN PERIPHERAL BLOOD. SINGLE‐CENTER CASE SERIES AND LITERATURE REVIEWMartín Moro, F / Martín Rubio, I / Alonso, R / López, C / Marquet, J / Herrera, F / Delgado Trillo, I / Herrera, P / García Vela, J. A et al. | 2021
-
SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMAKarmali, R. / Donovan, A. / Wagner‐Johntson, N. / Messmer, M. / Mehta, A. / Anderson, J. K. / Reddy, N. / Kovach, A. E. / Landsburg, D. J. / Glenn, M. et al. | 2021
-
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORKNovak, U. / Fehr, M. / Schär, S. / Dreyling, M. / Scheubeck, G. / Ramadan, S. / Zucca, E. / Zander, T. / Hess, G. / Mey, U. et al. | 2021
-
DIFFUSE LARGE B‐CELL LYMPHOMA IN ELDERLY PATIENTS: OUTCOME IN REAL‐WORLD CLINICAL PRACTICEMarques, B. / Duarte, S. / Afonso, C. / Lima, C. B. / Neves, D. / Lai, A. C. / Julião, M. J. / Roque, A. / Ruzickova, L. / Carda, J.P. et al. | 2021
-
REAL‐WORLD TREATMENT PATTERNS AND OUTCOMES OF 3455 PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA PATIENTS IN US ROUTINE CLINICAL PRACTICEKumar, A. / Martin, P. / Wang, M. / Qi, K. / Daly, K. / Parisi, L. / Zhu, A. / Salles, G. et al. | 2021
-
LIQUID‐BIOPSY BASED GENOTYPING OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)Heger, J.‐M. / Gödel, P. / Balke‐Want, H. / Altmüller, J. / Mattlener, J. / Dörr, H. / Weiss, J. / Sieg, N. / Kutsch, N. / Reinhardt, H. C. et al. | 2021
-
NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMABarrington, S. F. / Kirkwood, A. A. / Pike, L. C. / Guezennec, C. / Li, H. / le Blanc, M. / Poon, D. / Knopp, M. V. / Clifton‐Hadley, L. / Laubach, C. et al. | 2021
-
CAR‐T CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): THE EXPERIENCE OF THE FRENCH NETWORK FOR OCULO‐CEREBRAL LYMPHOMAS (LOC)Alcantara, M. / Houillier, C. / Le Garff‐Tavernier, M. / Souchet, L. / Roos‐Weil, D. / Morel, V. / Uzunov, M. / Metz, C. / Nguyen‐Quoc, S. / Jacque, N. et al. | 2021
-
LYMFOREST‐25: PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELSOrgueira, A. Mosquera / López, M. Cid / Raindo, A. Peleteiro / Díaz Arias, J. Án. / Pérez, M. S. González / Rodríguez, B. Antelo / Pérez, L. Bao / Ferro, R. Ferreiro / Santos, C. Aliste / Encinas, M. M. Pérez et al. | 2021
-
CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMARejeski, K. / Perez, A. / Sesques, P. / Berger, C. / Jentzsch, L. / Mougiakakos, D. / Frölich, L. / Ackermann, J. / Bücklein, V. / Blumenberg, V. et al. | 2021
-
PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONSTreon, S. / Buske, C. / Thomas, S. / Branagan, A. / Dimopoulos, M. / Castillo, J. J. / Garzon, F. / Tang, W. / Ronan, R. / Seyffert, S. et al. | 2021
-
A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMASMichot, J.‐M. / Carpio, C. / Nastoupil, L. / Chavez, J. / Feldman, T. / Ferrari, S. / Morillo, D. / Bachy, E. / Pinto, A. / Kuruvilla, J. et al. | 2021
-
COMPREHENSIVE ACTIVATION PROFILING OF TABELECLEUCEL, AN OFF‐THE‐SHELF, ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPYRuiz, F. / Jehng, T. / Spindler, T. / Munson, D. / Karlen, J. / Thota, V. / Wang, A. / Chuan, J. / Yedwabnick, M. / Dubovsky, J. et al. | 2021
-
CLINICAL AND RADIOGRAPHIC FACTORS PRIOR TO CAR T‐CELL THERAPY ACCURATELY IDENTIFY RELAPSED/REFRACTORY LYMPHOMA PATIENTS AT HIGH RISK FOR PROGRESSION AND POOR SURVIVALJodon, G. / Colton, M. D. / Cai, A. R. / Haverkos, B. / Morgan, R. / Kamdar, M. et al. | 2021
-
DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL)Tucci, A. / Merli, F. / Fabbri, A. / Mancuso, S. / Sartori, R. / Storti, S. / Luminari, S. / Mammi, C. / Marcheselli, L. / Arcari, A. et al. | 2021
-
PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMATun, A. M / Maliske, S / Wang, Y / Maurer, M. J / Micallef, I. N / Inwards, D. J / Porrata, L. F / Rosenthal, A. C / Kharfan‐Dabaja, M / Orme, J et al. | 2021
-
DISSECTING THE GENETICS OF DIFFERENT ANATOMICAL COMPARTMENTS OF SMALL LYMPHOCYTIC LYMPHOMA WITH A MULTIREGIONAL SEQUENCING APPORACHMoia, R. / Favini, C. / Ferri, V. / Terdi Di Bergamo, L. / Schipani, M. / Forestieri, G. / Sagiraju, S. / Andorno, A. / Rasi, S. / Talotta, D. et al. | 2021
-
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSAHerbaux, C. / Schiano de Colella, J. M. / Thieblemont, C. / Guidez, S. / Ysebaert, L. / Tilly, H. / Le Gouill, S. / Houot, R. / Bachy, E. / Laurent, C. et al. | 2021
-
DO CELL‐OF‐ORIGIN, DOUBLE EXPRESSER, AND DOUBLE HIT STATUS AFFECT OUTCOMES IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL)? A PROSPECTIVE OBSERVATIONAL STUDYDesai, S. H. / Mwangi, R. / Maurer, M. / King, R. / Cerhan, J. / Feldman, A. / Habermann, T. / Farooq, U. / Thompson, C. / Wang, Y. et al. | 2021
-
BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFEIonova, T. / Andrievskikh, M. / Amdiev, A. / Baryakh, E. / Chang, V. / Endakova, A. / Fadeeva, N. / Husainova, G. / Ivanov, V. / Kaplanov, K. et al. | 2021
-
SARS‐COV‐2 INFECTION IN 50 PATIENTS WITH PRIMARY CNS LYMPHOMA: PRESENTATION, EFFECTS ON TUMOR TREATMENT AND OUTCOME IN A SERIES OF THE INTERNATIONAL PCNSL COLLABORATIVE GROUPFerreri, A. J. M. / Steffanoni, S. / Calimeri, T. / Laurenge, A. / Fox, C. P. / Soussain, C. / Grommes, C. / Sassone, M. C. / Touat, M. / Boot, J. et al. | 2021
-
CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)LaCasce, A. S. / Dockter, T. / Ruppert, A. / Kostakoglu, L. / Schöder, H. / Hsi, E. D. / Bogart, J. A. / Cheson, B. D. / Wagner‐Johnston, N. D. / Abramson, J. S. et al. | 2021
-
PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMASChiu, C. W. / Hiemstra, I. H. / ten Hagen, W. / Snijdewint‐Nkairi, R. / de Jong, B. / Garrido Castro, P. / Kweekel, C. / Oliveri, R. S. / Elliot, B. / Wielgos‐Bonvallet, M. et al. | 2021
-
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)Pirosa, M. C. / Orsucci, L. / Feugier, P. / Tani, M. / Ghesquieres, Hervé / Musuraca, G. / Baldini, L. / Merli, F. / De Renzis, B. / Gyan, E. et al. | 2021
-
A SINGLE BLOOD TEST IS ABLE TO CLASSIFY DLBCL PATIENTS IN THREE PROGNOSTIC CLUSTERS AT DIAGNOSISMartín Moro, F. / Marquet Palomanes, J. / González Rodríguez, A. / Delgado Trillo, I. / López, C. / Herrera, F. / Villarrubia Espinosa, J. / Moreno Jiménez, G. / García Vela, J. A. / López Jiménez, F. J. et al. | 2021
-
A NEW OPTION IN PAIN PREVENTION WITH BLISS©, A DIGITAL THERAPEUTIC SOLUTION LEVERAGING VIRTUAL REALITY: RESULTS OF A FRENCH OPEN‐LABEL MULTICENTER RANDOMIZED PHASE III STUDY (REVEH TRIAL)Septans, A.‐L. / Le Dû, K. / Maloisel, F. / Vanquaethem, H. / Schmitt, A. / Le Goff, M. / Moles, M.‐P. / Zinger, M. / Bourgeois, H. / Peron, M. et al. | 2021
-
CAMRELIZUMAB COMBINED WITH GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMAXie, Y. / Mi, L. / Zheng, W. / Ping, L. / Lin, N. / Tu, M. / Zhang, C. / Ying, Z. / Liu, W. / Deng, L. et al. | 2021
-
BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDYGastinne, T. / Bouabdallah, K. / Moatti, H. / Tessoulin, B. / Shiano del colella, J. M. / Lamy, T. / Casasnovas, O. / Borel, C. / Stamatoullas, A. / Gac, A. C. et al. | 2021
-
MTV, TLG AND SUV MAX AS PROMISING PARAMETERS TO PREDICT EARLY RESPONSE IN PATIENTS WITH HL TREATED WITH ABVD. A RETROSPECTIVE SUB‐ANALYSIS OF THE GATLA‐LH‐05 TRIALIorio, J. / Eleta, M. / Plates, V. / Fiad, L. / Riddick, M. / Pavlovsky, A. et al. | 2021
-
A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMASKhan, N. / Noor, S. / Geller, S. / Khodadoust, M. S. / Kheterpal, M. / Hancock, H. / Davey, T. / Ryu, S. / Perez, L. / Lares, A. et al. | 2021
-
INTESTINAL T‐CELL LYMPHOMAS: MOLECULAR INTEGRATIVE ANALYSIS RECOGNIZES DIFFERENT THERAPEUTIC TARGETS FOR EACH SUBTYPEManso, R / Rodriguez, M / Chamizo, C / Pérez, N / Alonso‐Alonso, R / Minguez, P. A / Borregon, J / Baez‐Duran, E / Casas‐del Pozo, E. M / Piris, M. A et al. | 2021
-
CFT7455: A NOVEL, IKZF1/3 DEGRADER THAT DEMONSTRATES POTENT TUMOR REGRESSION IN A SPECTRUM OF NHL XENOGRAFT MODELSPerino, S / Class, B / Henderson, C / Isasa, M / Kirby, R. J / Agafonov, R. V / Chaturvedi, P / Eron, S. J / Good, A / Hart, A. A et al. | 2021
-
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMASIshitsuka, K / Izutsu, K / Maruyama, D / Makita, S / Jacobsen, E. D / Horwitz, S / Kusumoto, S / Allen, P / Porcu, P / Imaizumi, Y et al. | 2021
-
GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTSCarlo‐Stella, C / Hutchings, M / Offner, F. C / Morschhauser, F / Bachy, E / Crump, M / Sureda, A / Iacoboni, G / Haioun, C / Perez‐Callejo, D et al. | 2021
-
A GENE SIGNATURE TO PREDICT RISK OF TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMAFernandez‐Miranda, I. / Dominguez, M. / Pedrosa, L. / Gomez, S. / Gonzalez‐Rincon, J. / Espinet, B. / Climent, F. / Cruz, F. de la / Martin‐Acosta, P. / Colomo, L. et al. | 2021
-
COMPARATIVE EFFICACY OF TISAGENLECLEUCEL (TISA‐CEL) AND LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)Maziarz, R. T. / Zhang, J. / Yang, H. / Agarwal, A. / Tang, W. / Martinez‐Prieto, M. / Bollu, V. / Kuzan, D. / Schuster, S. J. / Kersten, M. J. et al. | 2021
-
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDYGenta, S / Ghilardi, G / Cascione, L / Juskevicius, D / Tzankov, A / Schär, S / Giovanella, L / Hayoz, S / Mamot, C / Dirnhofer, S et al. | 2021
-
ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)Pagel, J. / Reddy, N. / Jagadeesh, D. / Stathis, A. / Asch, A. S. / Salman, H. / Kenkre, V. P. / Soumerai, J. D. / Llorin‐Sangalang, J. / Gorbatchevsky, I. et al. | 2021
-
ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAYTerzi di Bergamo, L / Forestieri, G / Loh, J. W / Singh, A / Spina, V / Zucchetto, A / Condoluci, A / Faderl, M / Koch, R / Bruscaggin, A et al. | 2021
-
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIALTausch, E / Schneider, C / Yosifov, D / Robrecht, S / Zhang, C / Al‐Sawaf, O / Eichhorst, B / Fink, A.‐M / Bloehdorn, J / Kreuzer, K.‐A et al. | 2021
-
CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)Tam, C. S. L / Allan, J. N / Siddiqi, T / Kipps, T. J / Jacobs, R / Opat, S / Barr, P. M / Tedeschi, A / Trentin, L / Bannerji, R et al. | 2021
-
MANTLE CELL LYMPHOMA, A SINGLE CENTER EXPERIENCERoumelioti, A / Giatra, C / Dellatola, M / Dimitraki, E.‐K / Bouzani, M / Kanellis, G / Ikonopoulou, D / Kaouranis, K / El‐Gkotmi, N / Loutsidi, A et al. | 2021
-
IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL LIFE DATA FROM THE 'RETE EMATOLOGICA DEL LAZIO PER I LINFOMI' (RELLI)Mariani, S / Pelliccia, S / Bianchi, M. P / Di Rocco, A / Petrucci, L / Maiolo, E / Battistini, R / Fanelli, F / Tomei, G / Palombi, F et al. | 2021
-
CHIDAMIDE WITH PEL REGIMEN (PREDNISONE, ETOPOSIDE, LENALIDOMIDE) FOR ELDER OR FRAIL PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE BCELL LYMPHOMAWang, Y. / Xue, H. et al. | 2021
-
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIAHillmen, P. / Byrd, J. C. / Ghia, P. / Kater, A. P. / Chanan‐Khan, A. / Furman, R. R. / O'Brien, S. / Yenerel, M. N. / Illes, A. / Kay, N. et al. | 2021
-
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSGCramer, P / Fürstenau, M / Robrecht, S / Giza, A / Fink, A. M / Fischer, K / Langerbeins, P / Al Sawaf, O / Tausch, E / Schneider, C et al. | 2021
-
THE ROLE OF FDG‐PET/CT AND BONE MARROW BIOPSY IN DETECTING BONE MARROW INVOLVEMENT IN THE INITIAL STAGING OF FOLLICULAR LYMPHOMA: AN ANALYSIS OF ACCURACY AND PROGNOSTIC IMPACTReguilón Gallego, L. / Chen Liang, T. / Martín Santos, T. / Salar, A. / Fernández González, M. / Celades, C. / Tomás Navarro, J. / Martínez, A.‐B. / Andreu, R. / Balaguer Rosello, A. et al. | 2021
-
ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMASanz‐Villanueva, L. / Díaz Crespo, F. / Martín Rojas, R. / Carbonell, D. / Chicano, M. / Suárez‐González, J. / Muñiz, P. / Menárguez, J. / Kwon, M. / Diez Martín, J. L. et al. | 2021
-
IMMUNE SUPPRESSION AND DYSFUNCTION IN THE TUMOR MICROENVIRONMENT IN LYMPHOMAAnsell, S.M et al. | 2021
-
COCHRANE HAEMATOLOGY REVIEWS TO INFORM WORLD HEALTH ORGANIZATION’S LIST OF ESSENTIAL MEDICINES ON CLINICAL VALUE OF HIGH‐PRIORITY CANCER MEDICINESPiechotta, V. / Hirsch, C. / Ernst, M. / Goldkuhle, M. / Moja, L. / Skoetz, N. et al. | 2021
-
NANOSTRING ANALYSIS OF MYCOSIS FUNGOIDES OFFERS CLUES TO BETTER UNDERSTAND MF PATHOGENESIS AND PROGRESSIONAlonso‐Alonso, R / Rodriguez, M / García‐Díaz, N / Vaqué, J. P / Tomás‐Roca, L / Cereceda, L / Rodriguez‐Pinilla, S. M / Córdoba, R / García, J. F / Rodriguez‐Peralto, J. L et al. | 2021
-
PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASESFehr, M / Lang, N / Rubio, L / Güsewell, S / Templeton, A.J. / Aeppli, S / Tsang, R / Hodgson, D / Moccia, A / Bargetzi, M et al. | 2021
-
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMAKarihtala, K. / Leivonen, S.‐K. / Karjalainen‐Lindsberg, M.‐L. / Östman, A. / Pellinen, T. / Leppä, S. et al. | 2021
-
RNA SEQUENCING REVEALS DIFFERENT GENE EXPRESSION IN MALE VERSUS FEMALE DIFFUSE LARGE B‐CELL LYMPHOMAGhione, P / Cortes Gomez, E / Torka, P / Sundaram, S / Mavis, C / Tabbo', F / Gu, J / Cacciapuoti, M. T / Yoffe, L / Wang, J et al. | 2021
-
A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GEMOX) VS RITUXIMAB PLUS GEMOX FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAHertzberg, M. / Ku, M. / Catalani, O. / Althaus, B. / Simko, S. / Gregory, G. P. et al. | 2021
-
FDG‐PET IMAGING AND RADIOMICS IN RESPONSE ASSESSMENT OF LYMPHOMA PATIENTS UNDERGOING CAR T‐CELL THERAPYCasadei, B. / Paccagnella, A. / Farolfi, A. / Argnani, L. / Malizia, C. / Paolani, G. / Santoro, M. / Della Gala, G. / Strolin, S. / Strigari, L. et al. | 2021
-
Towards Control Of Chronic Lymphocytic Leukemia With Targeted AgentsHallek, M et al. | 2021
-
WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMINGHilton, L. K / Collinge, B / Rushton, C. K / Ben‐Neriah, S / Dreval, K / Grande, B. M / Boyle, M / Meissner, B / Slack, G. W / Farinha, P et al. | 2021
-
CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)Zinzani, P. L. / Capra, M. / Özcan, M. / Lv, F. / Li, W. / Yañez, E. / Sapunarova, K. / Lin, T. / Jin, J. / Jurczak, W. et al. | 2021
-
UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMAPulsoni, A. / Tosti, M. E. / Ferrero, S. / Luminari, S. / Dondi, A. / Liberati, A. M. / Cenfra, N. / Renzi, D. / Zanni, M. / Boccomini, C. et al. | 2021
-
EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)Luminari, S. / Guerra, L. / Durmo, R. / Chauvie, S. / Peano, S. / Franceschetto, A. / Fallanca, F. / Tarantino, V. / Pinto, A. / Ghiggi, C. et al. | 2021
-
EFFICACY OF SALVAGE RADIOTHERAPY IN PATIENTS WITH RESIDUAL OR RECURRENT DIFFUSE LARGE B‐CELL LYMPHOMACosman, G / Dickson, S / Chin, V / Thompson, S / Gupta, S / Chin, Y et al. | 2021
-
SOMATIC ALTERATIONS IN FOLLICULAR LYMPHOMA ASSOCIATE WITH UNIQUE TUMOR‐CELL TRANCRIPTIONAL STATES AND TUMOR‐IMMUNE MICROENVIRONMENTSKrull, J. / Wenzl, K. / Manske, M. K. / Hopper, M. A. / Larson, M. C. / Sarangi, V. / Barman, P. / Serres, M. R. / Khan, S. / Novak, A. J. et al. | 2021
-
SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY CLL UNDER REAL‐LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVESchwaner, I. / Hebart, H. / Losem, C. / Wolff, T. / Huelsenbeck, J. / Schmidt, B. / Rossi, D. / Noesslinger, T. et al. | 2021
-
IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIALMartelli, M. / Zucca, E. / Botto, B. / Kryachok, I. / Ceriani, L. / Balzarotti, M. / Tucci, A. / Cabras, M. G. / Zilioli, V. R. / Rusconi, C. et al. | 2021
-
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSISDreger, P. / Ngoya, M. / Litovich, C. / Finel, H. / Herrera, A. F / Sauter, C. / Kharfan‐Dabaja, M. / Sureda, A. / Blaise, D. / Castagna, L. et al. | 2021
-
THE COMBINATION OF VENETOCLAX, LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA INDUCES HIGH RESPONSE RATES AND MRD UNDETECTABILITYPhillips, T. J. / Bond, D. / Devata, S. / Danilov, A. / Herrera, A. / Maddocks, K. / Wilcox, R. / Karimi, Y. / Carty, S. / Kaminski, M. et al. | 2021
-
PRIMARY ORAL CAVITY LYMPHOMAS (POCL). FEATURES OF 67 PATIENTS TREATED AT A SINGLE INSTITUTION IN ARGENTINAJozami, A. C. / Arriola, J. / Marquez, M. / Luchetta, P. / Annetta, I. / Diaz Velez, N. / Courreges, V. et al. | 2021
-
HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDYCheminant, M. / Burroni, B. / Le Bris, Y. / Chartier, L. / Oberic, L. / Ribrag, V. / Delfau, M.‐H. / Thieblemont, C. / Gressin, R. / Canioni, D. et al. | 2021
-
BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS FIRST SALVAGE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. EXPERIENCE AT DONOSTIA UNIVERSITY HOSPITAL, SPAINEsquisabel, B. Mendibil / Segurola, L. Ondarra / Mongelos, A. Altuna / Alzola, J. Iriondo / Murua, A. Zumalde / Oyarzabal, A. Arambarri / Rois Pego, N. F. / Etxetxipia, I. Zeberio et al. | 2021
-
TRIPLE POSITIVE (CD10+BCL6+MUM1+) DIFFUSE LARGE B‐CELL LYMPHOMAS IN ADULTS ARE A HETEROGENEOUS GROUP ENRICHED IN LARGE B‐CELL LYMPHOMAS WITH IRF4 REARRANGEMENTFrauenfeld, L. / Castrejon‐de‐Anta, N. / Ramis‐Zaldivar, J. E. / Otto, F. / Streich, S. / Salmerón‐Villalobos, J. / Mayer, A. / Steinhilber, J. / Pinyol, M. / Mankel, B. et al. | 2021
-
THE ROLE OF END OF TREATMENT PET CT EVALUATED BY DEAUVILLE FIVE‐POINT SCALE AS PROGNOSTIC ROLE IN HODGKIN LYMPHOMAAssanto, G. M. / Agrippino, R. / Lapietra, G. / De Luca, M. L. / Chiaravalloti, A. / Annechini, G. / D'Elia, G. M. / Ciotti, G. / Martelli, M. / Pulsoni, A. et al. | 2021
-
A PROSPECTIVE UKRAINIAN MULTICENTRE COHORT STUDY OF PET VALUE PROGNOSTIC ROLE IN PRIMARY PATIENTS WITH HODGKIN LYMPHOMA (HL): HIGHLIGHTING CLINICAL RELEVANCENovosad, O. / Pastushenko, I. / Gorbach, O. / Kozlov, V. / Mykhalska, L. / Kindrakevych, O. / Novikov, M. / Karnabeda, O. / Oliinichenko, O. / Kmetyuk, Y. et al. | 2021
-
EXTRANODAL NK/T‐CELL LYMPHOMA, NASAL TYPE AND HIV INFECTION: A MEXICAN DESCRIPTIVE SERIESCastillo‐llanos, R. / Ramírez‐Ibarguen, A. F. / Lome‐Maldonado, C. et al. | 2021
-
ARTIFICIAL INTELLIGENCE AND MEDICINE: PAST AND FUTUREGambardella, L.M et al. | 2021
-
BONE MARROW INFILTRATION ASSESSMENT BY FDG18‐PET: CAN THIS IMAGING TEST REPLACE BONE MARROW TREPHINE BIOPSY IN DIFFUSE LARGE B CELL LYMPHOMA STAGING?Duarte, S. / Afonso, C. / Marques, B. / Barros Lima, C. / Neves, D. / Lai, A. C. / Julião, M. J. / Roque, A. / Ruzickova, L. / Carda, J. et al. | 2021
-
TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLLWierda, W. G. / Dorritie, K. A. / Munoz, J. / Stephens, D. M. / Solomon, S. / Gillenwater, H. H. / Gong, L. / Yang, L. / Ogasawara, K. / Thorpe, J. et al. | 2021
-
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15)Maerevoet, M. / Casasnovas, O. / Cartron, G. / Morschhauser, F. / Thieblemont, C. / Bouabdallah, K. / Feugier, P. / Szablewski, V. / Becker, S. / Tilly, H. et al. | 2021
-
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAZinzani, P. L. / Caimi, P. F. / Carlo‐Stella, C. / Ai, W. / Alderuccio, J. P. / Ardeshna, K. M. / Hess, B. / Kahl, B. S. / Radford, J. / Solh, M. et al. | 2021
-
DIGITAL SPATIAL PROFILING OF DIFFUSE LARGE B‐CELL LYMPHOMAS REVEALS STING AS AN IMMUNE‐RELATED DETERMINANT OF SURVIVAL AFTER R‐CHOP THERAPYHoppe, M. M / Fan, S / Jaynes, P / Peng, Y / Liu, X / De Mel, S / Poon, L / Chan, E / Lee, J / Chee, Y. L et al. | 2021
-
PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPYFouquet, G. / Wartski, M. / Dechmi, A. / Willems, L. / Deau‐Fischer, B. / Franchi, P. / Descroocq, J. / Deschamps, P. / Clerc, J. / Bouscary, D. et al. | 2021
-
NEGATIVE SYNERGISM BETWENN THE COMBINATION OF STEROID AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) ON BONE METABOLISM, IN PATIENTS TREATED FOR LYMPHOMAPezzullo, L. / D'Addona, M. / Martorelli, C. / Mettivier, L. / Giudice, V. / Fontana, R. / Ferrara, I. / Luponio, S. / Guariglia, R. / Serio, B. et al. | 2021
-
BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALSPhillips, E. H. / Counsell, N. / Illidge, T. / Andre, M. / Aurer, I. / Fiaccadori, V. / Fortpied, C. / Neven, A. / Federico, M. / Clifton‐Hadley, L. et al. | 2021
-
GUT MICROBIOTA ROLE IN RESPONSE TO CHECKPOINT INHIBITOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL HODGKIN LYMPHOMA: AN INTERIM ANALYSIS FROM MICRO‐LINF STUDYCasadei, B. / Guadagnuolo, S. / Barone, M. / Turroni, S. / Argnani, L. / Brigidi, P. / Zinzani, P. L. et al. | 2021
-
A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI‐8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T‐CELL LEUKEMIA‐LYMPHOMA (ATL)Izutsu, K. / Utsunomiya, A. / Jo, T. / Yoshida, S. / Ando, K. / Choi, I. / Imaizumi, Y. / Kato, K. / Kurosawa, M. / Kusumoto, S. et al. | 2021
-
PHASE 3 TRIAL (GCT3013‐05) OF EPCORITAMAB VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Thieblemont, C. / Clausen, M. R. / Balari, A. S. / Zinzani, P. L. / Fox, C. P. / Kim, S. Y. / Vindelov, S. D. / Lugtenburg, P. et al. | 2021
-
EFFECTIVENESS OF THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAKogarko, I / Golenkov, A.K / Kataeva, E.V / Kogarko, B.S. / Ganeev, I.I et al. | 2021
-
BASELINE CIRCULATING TUMOUR DNA AND TOTAL METABOLIC TUMOUR VOLUME AS EARLY OUTCOME PREDICTORS IN AGGRESSIVE B‐CELL LYMPHOMA. A REAL LIFE PROSPECTIVE 112‐PATIENT COHORTLe Goff, E / Blanc‐Durand, P / Roulin, L / Loyaux, R / MBoumbae, D. L / Poullot, E / Robe, C / Benmaad, I / Gricourt, G / Aissat, A et al. | 2021
-
FRACTIONATED TOTAL‐BODY IRRADIATION AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM‐CELL SUPPORT IN PATIENTS WITH T‐CELL LYMPHOBLASTIC LYMPHOMAZhang, M / Fu, R. X / Ge, R. J / Sun, C. Z / Nan, F. F et al. | 2021
-
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLDVodicka, P / Benesova, K / Janikova, A / Prochazka, V / Belada, D / Mocikova, H / Steinerova, K / Duras, J / Karban, J / Hanackova, V et al. | 2021
-
IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R2)Lurain, K / Roshan, R / Ramaswami, R / Mangusan, R / Widell, A / Ekwede, I / Ziegelbauer, J. M / Uldrick, T. S / Whitby, D / Yarchoan, R et al. | 2021
-
PRIMARY CENTRAL NERVOUS SYSTEM POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (CNS‐PTLD): A 20 YEARS RETROSPECTIVE SINGLE CENTER EXPERIENCELang, N. / De la Torre, A. / Kridel, R. / Prica, A. / Crump, M. / Kukreti, V. / Kuruvilla, J. / Tsang, R. / Hodgson, D. / Rodin, D. et al. | 2021
-
RISK MODEL FOR CENTRAL NERVOUS SYSTEM DISEASE IN T‐LYMPHOBLASTIC LYMPHOMA: A SINGLE‐CENTER EXPERIENCEFeng, X. / Gao, Y. / Li, L. / Li, X. / Sun, Z. / Wu, J. / Wang, X. / Fu, X. / Zhang, L. / Zhang, M. et al. | 2021
-
DERIVATION AND VALIDATION OF A NOVEL LIPID‐COVERED PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED MATURE T AND NK CELL LYMPHOMASLu, T. / Fang, X. / Jiang, Y. / Liu, J. / Cai, Y. / Hu, S. / Ding, M. / Wang, X. / Zhou, X. et al. | 2021
-
SYNERGISTIC ANTICANCER EFFECT OF COMBINED CHIDAMIDE AND ETOPOSIDE TREATMENT AGAINST NK/T CELL LYMPHOMASong, W. / Shi, C. / Gao, Y. et al. | 2021
-
PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417Cheah, C. Y. / Verner, E. / Tam, C. S. / Hilger, J. / Gao, Y. / Huang, J. / Simpson, D. / Opat, S. et al. | 2021
-
SURVIVAL INDEPENDENT PREDICTIVE VALUE OF INTERIM FDG18‐PET IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMADuarte, S. / Afonso, C. / Marques, B. / Barros Lima, C. / Neves, D. / Lai, A. C. / Julião, M. J. / Roque, A. / Ruzickova, L. / Carda, J. et al. | 2021
-
UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMABúa, B. Rey / Jiménez‐Ubieto, A. / Blanco, J. J. Sánchez / Abrisqueta, P. / Gutiérrez, A. / Ramírez‐Páyer, Án. / Giné, E. / Etxetxipia, I. Zeberio / Terol, M. José / Cruz, F. de la et al. | 2021
-
STEM CELL MOBILIZATION AFTER TREATMENT WITH BENDAMUSTINE IN PATIENTS WITH HODGKIN AND B‐CELL NON‐HODGKIN LYMPHOMAS. RESULTS AT DONOSTIA UNIVERSITY HOSPITAL, SPAINMendibil Esquisabel, B. / Ferreiro Martinez, J. J. / Zeberio Etxetxipia, I. / Altuna Mongelos, A. / Iriondo Alzola, J. / Zumalde Murua, A. / Arambarri Oyarzabal, A. / Rois Pego, N. F. / Alkorta Eizagirre, A. et al. | 2021
-
COMPARATIVE EVALUATION OF RADIATION THERAPY TECHNIQUES FOR MEDIASTINUM IRRADIATION IN LYMPHOMA PATIENTS USING IMRT, B‐VMAT, 3DCRTFomintseva, M. / Vinogradova, Y. / Ilyin, N. / Shenderova, I. / Storozhenko, L. / Vasilieva, A. et al. | 2021
-
RISK OF HEMOLYMPHOPOIETIC NEOPLASM BEFORE AND AFTER THYROID CANCER. A POPULATION‐BASED STUDY IN ITALY, 1998‐2012Mattioli, V. / Crocetti, E. / Dal Maso, L. / Buzzoni, C. / Franceschi, S. / Serraino, D. / Vaccarella, S. / Ferretti, S. / Busco, S. / Fedeli, U. et al. | 2021
-
MALT1 DEGRADATION FOR THE TREATMENT OF ACTIVATED B‐CELL TYPE DIFFUSE LARGE B‐CELL LYMPHOMASeshadri, M. R / Fontán, L / Scott, D / Hatcher, J / Sreevatsan, P / Du, G / Qiao, Q / Wu, H / Us, I / Xia, M et al. | 2021
-
SUBCUTANEOUS PANNICULITIS‐LIKE T‐CELL LYMPHOMA: MOLECULAR AND MUTATIONAL CHARACTERIZATION COMPARED WITH LUPUS PANNICULITIS AND HISTOPATHOLOGIC OVERLAPPING CASESMachan, S / Rodriguez, M / Manso, R / Borregon, J / Chamizo, C / Alonso‐Alonso, R / Pérez Buira, S / Rodríguez‐Peralto, J. L / Cerroni, L / Cereceda, L et al. | 2021
-
POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIALDiefenbach, C / Abrisqueta, P / Gonzalez-Barca, E / Panizo, C / Arguinano Perez, J. Maria / Miall, F / Bastos-Oreiro, M / Lopez-Guillermo, A / Banerjee, L / McMillan, A et al. | 2021
-
RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIALGallamini, A. / Walewski, J. / Rambaldi, A. / Viviani, S. / Sureda, A. / André, M. / Rossi, C. / Moccia, A. / Zucca, E. / Rossi, D. et al. | 2021
-
A PHASE II STUDY OF ANTI‐PD‐1 SINTILIMAB IN COMBINATION WITH CHIDAMIDE AND AZACITIDINE IN REFRACTORY AND RELAPSED PERIPHERAL T‐CELL LYMPHOMAYing, Z. / Song, Y. / Wang, X. / Lin, N. / Xie, Y. / Du, T. / Tang, Y. / Zhu, J. et al. | 2021
-
SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITYHutchings, M / Mous, R / Clausen, M. R / Johnson, P / Linton, K / Lewis, D. J / Chamuleau, M. E.D / Balari, A. S / Cunningham, D / DeMarco, D et al. | 2021
-
CARDIOVASCULAR EVENTS AMONG ADULT PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA TREATED WITH STANDARD OF CARE AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCELSteiner, R. / Banchs, J. / Koutroumpakis, E. / Becnel, M. / Gutierrez, C. / Strati, P. / Pinnix, C. / Feng, L. / Claussen, C. / Palaskas, N. et al. | 2021
-
RESISTANCE OF B‐CELL LYMPHOMAS TO CAR‐T CELL THERAPY IS ASSOCIATED WITH HISTOPHENOTYPICAL AND GENOMIC TUMOR CHANGES WHICH CAN INDUCE PROFOUND TRANS‐DIFFERENTIATIONLaurent, C. / Hamon, M. / Syrykh, C. / de Adélaï, J. / Guille, A. / Parrens, M. / Dartigues, P. / Bardet, A. / Mescam, L. / Schiano De Colella, J.‐M. et al. | 2021
-
PREDICTIVE VALUE OF QUANTITATIVE 18F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMADriessen, J / Zwezerijnen, G. J. C / Schöder, H / Moskowitz, A. J / Kersten, M. J / Moskowitz, C. H / Eertink, J. J / van de Brug, T / de Vet, H. C. W / Hoekstra, O. S et al. | 2021
-
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE ERA OF NOVEL THERAPIES‐ A RETROSPECTIVE ANALYSIS BY POLISH LYMPHOMA RESEARCH GROUPSzlauer‐Stefańska, A. T / Sawicki, W / Paszkiewicz‐Kozik, E / Romejko‐Jarosińska, J / Czerw, T / Giebel, S et al. | 2021
-
PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPYKurtz, D. M / Chabon, J. J / Soo, J / Co Ting Keh, L / Alig, S / Schultz, A / Jin, M. C / Scherer, F / Craig, A. F. M / Liu, C. L et al. | 2021
-
LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)Duell, J / Maddocks, K. J / González‐Barca, E / Jurczak, W / Liberati, A. M / Obr, A / Gaidano, G / Abrisqueta, P / André, M / Dreyling, M et al. | 2021
-
DOSE‐ADJUSTED EPOCH‐RITUXIMAB OR INTENSIFIED B‐NHL‐BFM‐TYPE THERAPY FOR PEDIATRIC PRIMARY MEDIASTINAL B‐CELL LYMPHOMAKnörr, F / Zimmermann, M / Attarbaschi, A / Kabíčková, E / Maecker‐Kolhoff, B / Ruf, S / Kühnle, I / Ebinger, M / Garthe, A.‐K / Oschlies, I et al. | 2021
-
UPDATED EFFICACY AND SAFETY RESULTS OF ORELABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LEUKEMIAXu, W. / Song, Y. / Wang, T. / Yang, S. / Liu, L. / Hu, Y. / Zhang, W. / Zhou, J. / Gao, S. / Ding, K. et al. | 2021
-
TIME‐TO‐RESPONSE FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B CELL NON‐HODGKIN LYMPHOMA TREATED WITH POLATUZUMAB‐BASED THERAPYHughes, M. E. / Nasta, S. D. / Gerson, J. N. / Svoboda, J. / Chong, E. A. / Schuster, S. J. / Barta, S. K. / Robinson, K. W. / Landsburg, D. J. et al. | 2021
-
HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSYMeriranta, L / Alkodsi, A / Pasanen, A / Lepistö, M / Blaker, Y. N / Jørgensen, J / Mapar, P / Björkholm, M / Jerkeman, M / Holte, H et al. | 2021
-
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDYZinzani, P. L. / Santoro, A. / Gritti, G. / Brice, P. / Barr, P. M. / Kuruvilla, J. / Cunningham, D. / Kline, J. / Johnson, N. A. / Mehta‐Shah, N. et al. | 2021
-
DOUBLE‐HIT (DHL) AND TRIPLE‐HIT LYMPHOMAS (THL): REAL LIFE EXPERIENCE OF 46 CONSECUTIVE PATIENTS FROM A SINGLE INSTITUTION IN SPAINGonzalez Barca, E. M. / Sancho, J. M. / Rovira, J. / Kelleher, N. / Kara, M. / Encuentra, M. / Domingo Domenech, E. / Oliveira, A. C. / Ribera, J. M. / Escoda, L. et al. | 2021
-
USE OF METHOTREXATE, WHATEVER KIDNEY FUNCTION, WITH A SIMPLE ALGORITHM, RADICALLY CHANGES THE PROGNOSIS OF POST‐TRANSPLANT CNS LYMPHOMASChoquet, S. / Lavaud, A. / Boussen, I. / Roos‐Weil, D. / Morel, V. / Uzunov, M. / Solorzano, S. / Le Garff, M. / Leblond, v. et al. | 2021
-
HIGHLY MULTIPLEX TISSUE IMAGING OF DLBCL IDENTIFIES NOVEL PATHOLOGICAL FEATURES PREDICTIVE OF OVERALL SURVIVALMcNally, D. R / Ravichandran, H / Tam, W / Steidl, C / Scott, D. W / Melnick, A / Elemento, O et al. | 2021
-
FDG‐PET/CT‐GUIDED REBIOPSY MAY FIND CLINICALLY UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSERajamäki, A. / Sunela, K. / Kuitunen, H. / Sorigue, M. / Kuittinen, O. et al. | 2021
-
MYC, BCL2 AND BCL6 COEXPRESSION PATTERNS AT SINGLE‐CELL RESOLUTION RE‐DEFINE DOUBLE EXPRESSOR LYMPHOMASHoppe, M. M / Jaynes, P / Fan, S / Peng, Y / Hoang, P. M / Liu, X / De Mel, S / Poon, L / Chan, E / Lee, J et al. | 2021
-
CURRENT ROLE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA IN THE ERA OF NEW IMMUNOTHERAPEUTIC AND TARGETED THERAPIES. THE GETH/GELTAMO EXPERIENCEGutierrez, A. / Bento, L. / Novelli, S. / Gutierrez, G. / Salas, Q. / Bastos‐Oreiro, M. / Perez, A. / Hernani, R. / Viguria, M. C. / Lopez‐Godino, O. et al. | 2021
-
A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)Ferrero, S. / Moia, R. / Cascione, L. / Zaccaria, G. M. / Rinaldi, A. / Alessandria, B. / Grimaldi, D. / Favini, C. / Evangelista, A. / Schipani, M. et al. | 2021
-
PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORKPott, C. / Macintyre, E. / Delfau, M.‐H. / Weiß, A. / Schilhabel, A. / Soehlbrand, A. / Kehden, B. / Darzentas, N. / Kotrova, M. / Schoen, F. et al. | 2021
-
THE TOPOLOGY OF MYC REARRANGEMENTS IN DOUBLE‐HIT LYMPHOMA IS CONSTRAINED BY THE PRECEDING IGH‐BCL2 REARRANGEMENT – AN LLMPP PROJECTHilton, L. K. / Collinge, B. / Ben‐Neriah, S. / Grande, B. M. / Slack, G. W. / Farinha, P. / Miyata‐Takata, T. / Cook, J. R. / Ott, G. / Rosenwald, A. et al. | 2021
-
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMASworder, B / Kurtz, D. M / Alig, S / Frank, M. J / Macauley, C. W / Garofalo, A / Shukla, N / Sahaf, B / Esfahani, M. S / Sheybani, N et al. | 2021
-
CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLSBrouwer‐Visser, J / Fiaschi, N / Deering, R. P / Dhanik, A / Cygan, K. J / Zhang, W / Jeong, S / Pourpe, S / Boucher, L / Hamon, S et al. | 2021
-
RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALSAurer, I. / Neven, A. / Fiaccadori, V. / Counsell, N. / Phillips, E. / Clifton‐Hadley, L. / Fortpied, C. / Andre, M. / Federico, M. / Barrington, S. et al. | 2021
-
DO WE STICK TO INTERNATIONAL GUIDELINES WHEN TREATING EARLY STAGE HODGKIN LYMPHOMA?Oliver, A. C. / Irigoin, V. / Bradvica, V. / Lema, V. / Landoni, A. I. / Ambrosoni, C. / Kollar, P. / Remedi, A. / Damiano, S. / Muxi, P. et al. | 2021
-
BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAINDomingo Domenech, E. / Sancho Cia, J. M. / Gonzalez Barca, E. / Kelleher, N. / Rodriguez‐Luaces, M. / Rovira, J. / Verdesoto, S. / Encuentra, M. / Blazevic, D. / Oliveira, A. et al. | 2021
-
IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASISDevin, J. / Cañeque, T. / Lin, Y.‐L. / Mondoulet, L. / Veyrune, J.‐L. / Abouladzé, M. / Garcia de Paco, E. / Gadacha, O. / Cartron, G. / Pasero, P. et al. | 2021
-
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1ST FLOR STUDYHawkes, E. A. / Lee, S. T. / Chong, G. / Gilbertson, M. / Grigg, A. / Churilov, L. / Fancourt, T. / Keane, C. / Ritchie, D. / Koldej, R. et al. | 2021
-
THE POTENTIAL EFFICACY AND MECHANISM OF BENDAMUSTINE IN ENTRA‐NODAL NK/T CELL LYMPHOMAFeng, X. / Gao, Y. / Li, H. / Jin, M. / Song, W. / Li, Z. / Zhang, M. et al. | 2021
-
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIESLe Gouill, S. / Bachy, E. / Di Blasi, R. / Cartron, G. / Beauvais, D. / Le Bras, F. / Gros, François‐X. / Choquet, S. / Bories, P. / Rubio, Marie‐Thérès. et al. | 2021
-
PRELIMINARY ACTIVITY OF DEVIMISTAT (CPI 613) IN PATIENTS WITH RELAPSED OR REFRACTORY BURKITT LYMPHOMA/LEUKEMIANikolaenko, L. / Pardee, T. S. / Steiner, R. / Abramson, J. S. / Horwitz, S. / Matasar, M. / Owens, C. / Rodriguez‐Rivera, I. / Straus, D. / Luther, S. et al. | 2021
-
INFLUENCE OF EPSTEIN BARR VIRUS (EBV) EXPRESSION ON CD4+ T CELLS AT THE MICROENVIRONMENT IN PEDIATRIC HODGKIN LYMPHOMAJimenez, O / Preciado, M. V / Matteo, E. De / Chabay, P et al. | 2021
-
FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR LYMPHOMAAssanto, G. M. / Ciotti, G. / Brescini, M. / Agrippino, R. / Lapietra, G. / De Luca, M. L. / Annechini, G. / D'Elia, G. M. / Chiaravalloti, A. / Del Giudice, I. et al. | 2021
-
AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPSMarouf, A. / Cottereau, A. S. / Kanoun, S. / Deschamps, P. / Franchi, P. / Meignan, M. / Sibon, D. / Gastinne, T. / Borel, C. / Hammoud, M. et al. | 2021
-
BEGEV SALVAGE REGIMEN IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCEMorigi, A. / Stefoni, V. / Argnani, L. / Carella, M. / Casadei, B. / Lolli, G. / Broccoli, A. / Pellegrini, C. / Nanni, L. / Coppola, P. E. et al. | 2021
-
HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA USING REAL‐WORLD DATA FROM FIVE COUNTRIESCool, C. / Feng, C. / Wade, S. / Rau, R. / Ching, K. / Nyamutswa, L. / Viswanathan, H. / Kharabi, B. / Duvall, A. et al. | 2021
-
HOW MACHINE LEARNING CAN ENHANCE CLINICAL DEVELOPMENTTrichelair, P et al. | 2021
-
A WIDE T‐CELL EXHAUSTION PATTERN IS FREQUENTIN THE TUMOR MICROENVIRONMENT OF RELAPSED/REFRACTORY B‐CELL LYMPHOMA PATIENTS AND COULD BE CIRCUMVENTED BY PDL1 BLOCKADELaurent, C / Syrykh, C / Herbaux, C / Gat, E / Gravelle, P / Tarte, K / Cartron, G / Xerri, L et al. | 2021
-
A UK POPULATION‐BASED STUDY OF NON‐HODGKIN LYMPHOMA IN TEENAGERS AND YOUNG ADULTS (TYA) DELAYED DIAGNOSIS AND DEATHCarr, R. / Stevens, K. / Anyaegbu, G. / Fidalgo, J. et al. | 2021
-
A PHASE IB STUDY OF AN ORAL PI3Kδ INHIBITOR LINPERLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMAQiu, L. / Jin, J. / Cen, H. / Zhou, K. / Xu, X. / Li, F. / Wu, T. / Yang, H. / Wang, Z. / Li, Z. et al. | 2021
-
TARGETING DLBCL‐DERIVED EXOSOMES PREVENTS NK CELL EXHAUSTION AND ELICITS POTENT ANTI‐TUMOR IMMUNITYLu, F / Pang, Y / Zhao, Y / Ye, J / Ji, C et al. | 2021
-
FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION (SGN35‐032, TRIAL IN PROGRESS)Jagadeesh, D. / Knowles, S. / Horwitz, S. M. et al. | 2021
-
HEPATOSPLENIC T CELL LYMPHOMA: CLINICAL CHARACTERISTICS AND SURVIVALBaidoun, F / Alhaj Moustafa, M / Tun, H. W / Hill, B. T / Jagadeesh, D et al. | 2021
-
CLINICAL CHARACTERISTICS AND OUTCOMES OF ADULT LYMPHOMA‐ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)Lee, C. Y / Wills Sanin, B / Vardhana, S. A / Moskowitz, A. J et al. | 2021
-
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDYSibon, D / Bisig, B / Bonnet, C / Bachy, E / Cavalieri, D / Fataccioli, V / Drieux, F / Bruneau, J / Lemonnier, F / Bossard, C et al. | 2021
-
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSESOlszewski, A. J / Avigdor, A / Babu, S / Levi, I / Eradat, H / Abadi, U / Holmes, H / McKinney, M / Woszczyk, D / Giannopoulos, K et al. | 2021
-
CLINICAL APPLICATION OF AN EX‐VIVO PLATFORM TO GUIDE THE CHOICE OF DRUG COMBINATIONS IN RELAPSED/REFRACTORY LYMPHOMA; A PROSPECTIVE STUDYDe Mel, S / Goh, J / Rashid, M. B. M. A / Zhang, X. Y / Jaynes, P / Liu, X / Poon, L / Chan, E / Lee, J / Chee, Y. L et al. | 2021
-
BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)Bartlett, N. L. / Yasenchak, C. A. / Ashraf, K. K. / Harwin, W. N. / Sims, R. B. / Nowakowski, G. S. et al. | 2021
-
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6Carlo‐Stella, C. / Depaus, J. / Hess, B. T. / Kingsley, E. / Zinzani, P. L. / Ungar, D. / Dai, V. / Wang, L. / Ardeshna, K. M. et al. | 2021
-
RELAPSE CHARACTERIZATION IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS UNDERGOING COMMERCIAL CAR‐T CELL THERAPY: EXPERIENCE FROM A SINGLE CENTREBastos‐Oreiro, M. / Bailén, R. / Silva, P. / Monsalvo, S. / Pérez Corral, A. / Carbonell, D. / Díaz Crespo, F. / Gómez‐Fernández, I. / Oarbeascoa, G. / Dorado, N. et al. | 2021
-
PATIENTS WITH OUT OF SPECIFICATION TISAGENLECLEUCEL CAN BE SALVAGED WITH A POINT‐OF‐CARE CAR T‐CELLS: AN OBSERVATIONAL INTENTION‐TO‐TREAT SINGLE‐CENTER ANALYSISS. Fried / R. Shouval / N. Varda‐Bloom / M. Besser / R. Yerushalmi / N. Shem‐Tov / I. Danylesko / E. Jacoby / S. Teihman / A. Shimoni et al. | 2021
-
SEROLOGICAL RESPONSES AFTER SARS‐COV‐2 VACCINATION FIRST DOSE IN PATIENTS WITH LYMPHOID MALIGNANCY: FIRST INTERIM ANALYSIS OF THE UK PROSECO STUDYLim, S.H. / Campbell, N. / Joseph‐Pietras, D. / Johnson, M. / Mundy, C. / Coleman, H. / Wynn, T. / Maynard, B. / Lown, R. / Bates, A. et al. | 2021
-
SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)Trotman, J. / Tedeschi, A. / Linton, K. / McKay, P. / Hu, B. / Chan, H. / Jin, J. / Sobieraj‐Teague, M. / Zinzani, P. L. / Coleman, M. et al. | 2021
-
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDYZhang, M / Xu, P / Wang, L / Cheng, S / Zhao, W et al. | 2021
-
CLINICAL CHARACTERISTICS AND OUTCOMES OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS, TREATED AND FOLLOWED IN A PUBLIC BRAZILIAN CENTERDuffles Amarante, G. B / Szor, R. S / Duran, A / Alves, L. B. d. O / Martinez, G / Pereira, J / Rocha, V. G et al. | 2021
-
THE CONTRIBUTION OF MONOCYTE‐TO‐PLATELET RATIO TO PREDICT OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA: A SINGLE‐CENTER SURVEYLorenzano, F / Santuccio, G / Caruso, L / Chiarenza, A / Figuera, A / Motta, G / Di Raimondo, F / Romano, A et al. | 2021
-
FOTEMUSTINE‐BASED THERAPY IN COMBINATION WITH RITUXIMAB AS FIRST‐LINE INDUCTION CHEMOTHERAPY FOLLOWED BY WBRT FOR NEWLY DIAGNOSED PCNSL: A PROSPECTIVE PHASE II TRIALWu, J / Gao, F / Zhang, L / Li, X / Li, L / Sun, Z / Wang, X / Fu, X / Zhang, X / Zhang, M et al. | 2021
-
R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)Rovira, J / González‐Barca, E / M. Sancho, J / Kelleher, N / Rodríguez, M / Fox, L / Parody, R / Martin, S / Vicent, A / Villarroel, J et al. | 2021
-
RHOA G17V POTENTIATES CD28 T195P MUTATION INDUCED NFAT TRANSCRIPTIONAL ACTIVITY UPON CD3/CD28 STIMULATIONVallois, D. / Missiaglia, E. / Bisig, B. / Juilland, Mél. Favre / Miazza, M. Thome / de Leval, L. et al. | 2021
-
INTRAVENOUS HIGH DOSE METHOTREXATE AS CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH HIGH RISK FOR CNS PROGRESSIONVillarreal, J. A. / Rovira, J. / Franch, M. / Encuentra, M. / Blazevic, D. / Rodriguez, M. / Kelleger, N. / Martín, S. / Oliveira, A. C. / Domingo Domenech, E. et al. | 2021
-
COMPREHENSIVE TRANSCRIPTOME ANALYSIS IDENTIFIES DISTINCT COMPETING ENDOGENOUS RNA NETWORK IN CHRONIC LYMPHOCYTIC LEUKEMIAZhang, Y. / Zhang, X. / Han, Y. / Tian, Z. / Hu, X. / Wang, X. et al. | 2021
-
LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDYDriessen, J. / Kersten, M. J. / Visser, L. / van den Berg, A. / Zijlstra, J. M. / Tonino, S. H. / Zwezerijnen, G. J. / Boellaard, R. / Lugtenburg, P. J. / Hutchings, M. et al. | 2021
-
MOLECULAR HIGH GRADE (MHG) GENE EXPRESSION PROFILE IN DLBCL IS ENRICHED AMONG PATIENTS WITH EARLY TREATMENT FAILUREBarrans, S. L / Cucco, F / Davies, J / van Hoppe, M / Mell, T / Mercer, K / Stanton, l / Caddy, J / Tooze, R / Burton, C et al. | 2021
-
PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMADiefenbach, C / Budde, E / Chavez, J / Lossos, I. S / Mehta, A / Dorritie, K / Kamdar, M / Negricea, R / Pham, S / Hristopoulos, M et al. | 2021
-
FIRST‐LINE IBRUTINIB + VENETOCLAX TREATMENT FOR MANTLE CELL LYMPHOMA IN OLDER PATIENTS OR THOSE WITH TP53 MUTATION: A NEW OPEN‐LABEL ARM OF THE PHASE 3 PCYC‐1143 SYMPATICO STUDYJurczak, W. / Tam, C. / Eckert, K. / Lin, J. / Neuenburg, J. K. / Wang, M. L. et al. | 2021
-
A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMAVilla, D. / Scott, D. W. / Morin, R. / Nakamura, H. / Larouche, J. F. / Cheung, M. / Johnson, N. / Elemary, M. / Keating, M. M. / Tonseth, P. et al. | 2021
-
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)Jurczak, W. / Zinzani, P. L. / Cunningham, D. / Yavrom, S. / Huang, W. / Gorbatchevsky, I. / Ribrag, V. et al. | 2021
-
FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGYChiappella, A. / Guidetti, A. / Dodero, A. / Bramanti, S. / Zinzani, P. / Santoro, A. / Casadei, B. / Di Rocco, A. / Carrabba, M. / Chiusolo, P. et al. | 2021
-
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIALGallamini, A / Rambaldi, A / Patti, C / Romano, A / Viviani, S / Bolis, S / Oppi, S / Trentin, L / Cantonetti, M / Sorasio, R et al. | 2021
-
HEMORRHAGIC MANIFESTATIONS OF LONG TIME ANTICOAGULANTS TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECIVING IBRUTINIBEmelina, E / Gendlin, G / Nikitin, I et al. | 2021
-
DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMACeriani, L / Milan, L / Cascione, L / Gritti, G / Dalmasso, F / Esposito, F / Schär, Säm / Bruno, A / Dirnhofer, S / Giovanella, L et al. | 2021
-
A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY| 2021
-
ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATIONBommier, C / Ruggiu, M / Monegier, A / Zucca, E / Thieblemont, C / Lambert, J et al. | 2021
-
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIALConconi, A. / Chiappella, A. / Orsucci, L. / Gaidano, G. / Ferreri, Andrés J.M. / Balzarotti, M. / Tucci, A. / Botto, B. / Moccia, A. / Vanazzi, A. et al. | 2021
-
PERVASIVE HYPERMUTATION OF SUPER‐ENHANCER REGIONS DYSREGULATES ONCOGENE EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMABal, E / Kumar, R / Hadigol, M / Holmes, A / Basso, K / Khiabanian, H / Pasqualucci, L / Dalla‐Favera, R et al. | 2021
-
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDYWu, J. Q. / Seymour, J. F. / Eichhorst, B. / Hillmen, P. / Kipps, T. / Langerak, A. W. / Owen, C. / Dubois, J. / Mellink, C. / van der Kevie‐Kersemaekers, A. et al. | 2021
-
PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH AT DIAGNOSIS (RDW) IN DIFFUSE LARGE B‐CELL LYMPHOMARaya, J.M. / López‐García, P. / Reyes, C. D. / Rodríguez‐Salazar, M.J. / De Bonis, C. / González‐González, B. / Hernández‐García, M. T. / Lakhwani, S. et al. | 2021
-
A CROSS‐SECTIONAL STUDY ON THE GLOBAL DIFFERENCES IN INFORMATION EXPERIENCES AND NEEDS OF PATIENTS WITH LYMPHOMA AND CLLWarwick, L. / Bamigbola, O. / Dren, N. et al. | 2021
-
TREATMENT AND OUTCOMES OF PATIENTS WITH POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER: A SINGLE CENTRE EXPERIENCEde Ramon Ortiz, C. / Samii, K. / Hadaya, K. / Avram, A. / Beauverd, Y. et al. | 2021
-
TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMAVilla, D. / Jiang, A. / Crosbie, N. / Rule, S. / McCulloch, R. / Visco, C. / Buege, M. J. / Kumar, A. / Bond, D. / Paludo, J. et al. | 2021
-
EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDYGiné, E. / De la Cruz, F. / Ubieto, A. Jiménez / Jiménez, J. López / García‐Sancho, A. Martín / Terol, M. J. / González‐Barca, E. / Casanova, M. / De la Fuente Burguera, A. / Niebla, A. Marín et al. | 2021
-
ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORTWang, M. / Salles, G. / Kumar, A. / Qi, K. / Daly, K. / Parisi, L. / Zhu, A. / Martin, P. et al. | 2021
-
RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMAVilla, D. / Hoster, E. / Hermine, O. / Klapper, W. / Szymczyk, M. / Bosly, A. / Unterhalt, M. / Freeman, C. L. / Scott, D. W. / Gerrie, A. S. et al. | 2021
-
THE MUTATIONAL LANDSCAPE OF DOUBLE/TRIPLE‐HIT HIGH‐GRADE B‐CELL LYMPHOMA WITH BCL2 REARRANGEMENT (DH/TH‐BCL2) – AN LLMPP PROJECTCollinge, B. J. / Hilton, L. K. / Wong, J. / Ben‐Neriah, S. / Alduaij, W. / Rushton, C. K. / Slack, G. W. / Farinha, P. / Miyata‐Takata, T. / Cook, J. R. et al. | 2021
-
ANALYSIS OF SPERMATOGENESIS BEFORE AND AFTER TREATMENT IN PATIENTS WITH HODGKIN LYMPHOMAGaudio, F. / Masciopinto, P. / Nardelli, C. / Vacca, M. P. / Laddaga, F. E. / Cicinelli, E. / Musto, P. et al. | 2021
-
COMBINATION OF RITUXIMAB‐LENALIDOMIDE‐IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA: A COHORT STUDY OF THE LOC NETWORKHouillier, C / Moluçon‐Chabrot, C. / Moles, M.‐P. / Willems, L. / Ahle, G. / Waultier, A. / Fornecker, L.‐M. / Hoang‐Xuan, K. / Soussain, C. et al. | 2021
-
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDYAnsell, S. M. / Bröckelmann, P. J. / von Keudell, G. / Lee, H. J. / Santoro, A. / Zinzani, P. L. / Collins, G. P. / Cohen, J. B. / De Boer, J. P. / Kuruvilla, J. et al. | 2021
-
RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIESVassilakopoulos, T. / Ferhanoglu, B. / Horowitz, N. / Mellios, Z. / Kaynar, L. / Zektser, M. / Symeonidis, A. / Piperidou, A. / Kalpadakis, C. / Akay, O. M. et al. | 2021
-
THE CD19/CD3 BISPECIFIC ANTIBODY WORK EFFECTIVELY AS ADJUNCT WITH IBRUTINIB ON THE TREATMENT OF B‐CELL LYMPHOMAYu, H. / Liu, W. / Mi, L. / Shu, S. / Zhang, W. / Ying, Z. / Chen, H. / Yan, X. / Shen, W. / Tu, G. et al. | 2021
-
RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)Luminari, S. / Galimberti, S. / Versari, A. / Tucci, A. / Boccomini, C. / Farina, L. / Zaja, F. / Marcheselli, L. / Ferrero, S. / Arcaini, L. et al. | 2021
-
A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMATorka, P. / Groman, A. / Wong, J. / Baysal, B. / Nichols, J. / Kader, A. / Mavis, C. / Jani Sait, S. / Block, A. / Przespolewski, E. et al. | 2021
-
INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078EDesai, S. / Laplant, B. / Macon, W. / Young, J. / King, R. / Wang, Y. / Inwards, D. / Micallef, I. / Johnston, P. B. / Porrata, L. F. et al. | 2021
-
OUTCOME OF LARGE B‐CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR‐T THERAPYKuhnl, A. / Kirkwood, A. A. / O'Reilly, M. / Sanderson, R. / Tholouli, E. / Patel, A. / Besley, C. / Iyengar, S. / Jones, C. / Latif, A.‐L. et al. | 2021
-
POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB FOR RELAPSED/REFRACTORY HIGH‐GRADE B‐CELL LYMPHOMA: THE UK EXPERIENCENorthend, M. / Wilson, W. / Osborne, W. / Fox, C. P. / Davies, A. J / El‐Sharkawi, D. / Phillips, E. H. / Sim, H. W. / Sadullah, S. / Shah, N. et al. | 2021
-
PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMAKumar, A. / Batlevi, C. / Drullinsky, P. / Grieve, C. / Laraque, L. / Joseph, A. / Mahajan, N. / Matasar, M. / Straus, D. / Zelenetz, A. et al. | 2021
-
SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE‐DENSE SHORT‐TERM THERAPY IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA AND MYC REARRANGEMENTFerreri, A. J. M / Angelillo, P / Erbella, F / Liberatore, C / Cattaneo, C / Verga, L / Lleshi, A / Allione, B / Facchetti, F / Ponzoni, M et al. | 2021
-
COSTIMULATORY MOLECULE OX40, TUMOR IMMUNE MICROENVIRONMENT AND RESPONSE TO IMMUNOCHEMOTHERAPY IN DIFFUSE LARGE B‐CELL LYMPHOMA: AN INTEGRATIVE ANALYSIS WITH MOLECULAR CHARACTERISTICSWang, X / Hong, Y / Li, Y / Guan, Q / Zhou, S / Qian, Z / Qiu, L / Li, L / Liu, X / Fu, K et al. | 2021
-
OUTCOMES OF PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUPGarcía‐Sancho, A. Martín / Izuzquiza, M. / Bastos‐Oreiro, M. / Baile, M. / Nistal, S. / Cortés, M. / Jiménez‐Ubieto, A. / Búa, B. Rey / Guillén‐García, H. / Cannata‐Ortiz, J. et al. | 2021
-
THE SURVIVAL OF 2852 PATIENTS WITH LYMPHOMA: A SINGLE CENTER STUDY FROM CHINAZhang, L. / Sun, Z. / Fu, X. / Wan, W. / Ge, J. / Xia, Y. / Xu, D. / Nan, F. / Yu, H. / Zhang, M. et al. | 2021
-
PRIORITISATION OF RELEVANT COCHRANE REVIEW TOPICS IN THE FIELD OF HAEMATOLOGYHirsch, C. / Jakob, T. / Tomlinson, E. / Estcourt, L. / Theurich, S. / Ocheni, S. / Skoetz, N. / Piechotta, V. et al. | 2021
-
SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCEZilioli, V. R. / Albano, D. / Arcari, A. / Merli, F. / Coppola, A. / Besutti, G. / Marcheselli, L. / Gramegna, D. / Muzi, C. / Manicone, M. et al. | 2021
-
POPULATION‐BASED COHORT STUDY OF THE EFFICACY OF BRENTUXIMAB‐VEDOTIN IN RELAPSED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA USING PUBLIC HEALTH ENGLAND DATAHalligan, S. / Grainge, M. J. / Martinez‐Calle, N. / Fox, C. P. / Bishton, M. et al. | 2021
-
CIRCULATING TUMOR DNA BY HIGH‐THROUGHPUT SEQUENCING OF T CELL RECEPTOR MONITORED TREATMENT RESPONSE AND PREDICTED TREATMENT FAILURE IN T CELL LYMPHOMASWang, W / Zhang, W / Zhang, Y / Gan, Y / Qian, L / Zhou, D et al. | 2021
-
CHARACTERIZATION OF THE ONCOGENIC PHENOTYPE IN EXTRANODAL NATURAL KILLER/T‐CELL LYMPHOMA, NASAL TYPE THROUGH GENE EXPRESSION PROFILE. SPANISH LYMPHOMA GROUP GELTAMOGonzález-Barca, E / Gato, L / Esteve, A / Sanz‐Pamplona, R / Tomás, L / Rodriguez, M / Martín García‐Sancho, A / Córdoba, R / Monter, A / Bastos, M et al. | 2021
-
FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20‐POSITIVE TUMORS, RITUXIMAB IN RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMASd'Amore, F / Leppä, S / Relander, T / Larsen, T. S / Brown, P / Jørgensen, J / Mannisto, S / Lugtenburg, P / Leivonen, S.‐K / Holte, H et al. | 2021
-
TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVALRivas‐Delgado, A. / López, C. / Nadeu, F. / Grau, M. / Rivero, A. / Bosch, J. / Alcoceba, M. / Gustavo, T. / Luizaga, L. / Barcena, C. et al. | 2021